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1  Summary  
 
  
Headache, including migraine, is a common and disabling neurobiological disorder which is 
under-recognized, under-treated, commonly mismanaged and it imposes a substantial health 
burden.  
The principle aim of my dissertation was to review the existing data about these findings in 
order to develop and validate scientific instruments to improve the methodology and the 
scientific value of future headache impact studies on which headache disease-management 
recommendations at EU level will be based upon. 
My dissertation’s working objectives were: 
• To review the literature published between 1988 and 2007 for studies reporting the 
prevalence and impact of headache disorders and new relevant review papers at 
European level from 2005-2007   
• To develop and validate a first scientific instrument in a questionnaire format for 
gathering headache impact information from a representative multi-cultural population 
sample of migraine sufferers  in Luxembourg  
• To develop and validate a second instrument in a questionnaire format for gathering 
headache prevalence and impact information in a standardized way from headache 
sufferers in Europe. 
 In my first study I made a literature survey in order to summarize what is known on the 
subject, as a support for my future studies to assess the prevalence and impact of primary 
headache disorders in Europe with similar methodology and the same research instrument.  
The analysis revealed that according to a recent health economic survey in Europe migraine is 
the most costly among the neurological disorders. Several studies suggest that migraine and 
other disorders lead to widespread suffering, reduction of quality of life, and marked 
impairment of participation, both in work and social activities. Most studies have yielded 
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relatively reliable data only for migraine, whereas the impact of tension-type headache is 
virtually unknown or only very incompletely known for most dimensions of headache impact. 
Some data do suggest, however, that this headache may be as important from a health 
economic and a public health perspective as migraine.  
These findings allowed me to analyze the gaps and to the collection of population-based data 
from various countries relevant for estimation of indirect (mostly absenteeism from work and 
reduced working efficiency when having headache) and direct costs (related to medication, 
consultations, investigations and hospitalisations). The impact on ability to get education and 
participate in the workforce should be taken into consideration as well as the impact on love 
life and family planning. To get a complete picture, one should also ask about the effect on 
the life of partners and children, and on the possible impact even when headache free (e.g. 
fear of the next attack). The quality of life of headache patients should be measured by 
validated instruments.  
In my second study we developed and validated a 77-item-self reporting questionnaire 
to run a pilot study to assess the burden of migraine (BURMIG), including headache 
characteristics, migraine associated disability, comorbidities, management, and the 
consequences on the patients lives. We translated BURMIG into 4 languages (French, 
Portuguese, German and English) and tested it in 130 headache patients (20 from pain clinics, 
17 from primary care doctors and 93 from the general public) in Luxembourg. We performed 
a linguistic and a face-content validation and tested the questionnaire for its 
comprehensiveness, internal consistency and for its test-retest-reliability at an interval of one 
month (completion rates were 79.6%, and 76,4%, for test and retest, respectively). Retest-
reliability for the different parts of the questionnaire varied between 0.6 to 1.0 (Kappa 
coefficient), with an intracorrelation coefficient of 0.7–1.0. The internal consistency was 
between 0.74 to 0.91 (Cronbach’s alpha).   
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These findings allowed me to propose the BURMIG questionnaire to evaluate the burden of 
migraine in the multicultural population of Luxemburg in four languages English, German, 
French and Portuguese. 
         Based on the results of my pilot study in Luxemburg with BURMIG questionnaire, we 
developed in my third study a 103-item-self reporting questionnaire (EUROLIGHT) to assess 
the burden of primary headache disorders on those affected by them including headache 
characteristics, associated disability, comorbidities, disease-management and quality of life. 
We validated the questionnaire in 5 languages with 426 headache patients (131 in UK, 60 in 
Italy, 107 in Spain, 83 in Germany/Austria, and 45 in France). After a linguistic and a face-
content validation we tested the questionnaire for comprehensibility, internal consistency and 
test-retest reliability at an interval of one month. In the different countries, response rates 
were between 73% and 100%. Completion rates over 90% were 69% and 82%. Test-retest 
reliability varied between -0.27 to 1.0 depending of the nature of the expected agreement. The 
internal consistency was between 0.69 and 0.91.  
These findings allowed me to propose the EUROLIGHT questionnaire to evaluate the burden 
of primary headache disorders at European level. It can be used in English, German, French, 
Italian and Spanish. Further language validations have already been done for Portuguese, 
Dutch and Lithuanian. 
    The studies show that primary headache disorders are disabling neurobiological 
disorders but under-recognized, under-treated and commonly mismanaged. With the support 
of major stakeholders we developed a first and then a second scientific instrument in a 
questionnaire format and we validated both instruments to gather qualitative as well as 
quantitative data that describe the clinical, economic and humanistic dimensions of primary 
headache disorders to produce systematic data to complement epidemiological evidence of 
the burden and disease management of primary headache disorders in Europe. 
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2  Introduction  
 
2.1 Headache Disorders and Public Health 
 
Headache is a symptom of a range of neurobiological disorders, including some of the most 
common and ubiquitous. Adults aged 20-50 years are the most likely sufferers (1) but children 
and adolescents are affected to (2). The term headache disorder encompasses a number of 
conditions which vary in severity, incidence and duration. As a consequence establishing their 
overall prevalence has been difficult. Migraine is the more thoroughly investigated, and better 
understood, Onset of migraine is from childhood onwards but most commonly in the 20s and 
30s (3)  (Figure 1) and relatively infrequently after the age of 40 years; therefore, prevalence 
increases from the first to fourth decades and thereafter declines (4) . Migraine may 
nevertheless be a significant health issue among children (5). 
Figure 1 Migraine prevalence related to age in men and women, average of 10 studies 
(Reproduced from Stovner et al 
(5)
 with permission from European Journal of 9eurology) 
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Overall, migraine has a variable prevalence worldwide. Over 12% of the general population  
have regular migraine attacks. The frequency of migraine attacks is highly variable, from 
1/year in some to more than 1/week in as many as 25% of sufferers (6). The average may be as 
high as 21 episodes per sufferer per year (7).  Extrapolation of migraine attack prevalence and 
attack incidence suggest that 3000 migraine attacks occur every day for each million.  
Probably everywhere, significantly more women are affected than men, in a ratio of 2-3:l. (8).  
Other forms of nearly every day headaches, estimated as high as 1 in 25 of adults, are 
associated with long-term morbidity.  
Tension-type headache is the most widespread of headache disorders (9) .Onset is often in the 
teenage years and prevalence peaks in the fourth decade and then declines (10) (Figure 2) 
 
Figure 2  Headache prevalence related to age in men and women, average of 3 studies  
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(Reproduced from Stovner et al (5) with permission from European Journal of 9eurology)  
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Overall, one-year prevalence may exceed 60% although it is apparently lower in some 
countries. A large part of the population have mild and infrequent tension-type headache 
(once monthly or less), with 20-30% experiencing headache episodes more often. Tension-
type headache is also more common in women, in a ratio of 1.5 :1 (8). 
What is undisputed is that migraine and tension-type headache are the most prevalent 
headache disorders and, both with disabling potential, they have the greatest impact on public 
health. Nearly all migraine sufferers and 60% of those with tension-type headache experience 
reductions in social activities and work capacity (11-14).
 
The World Health Organization (WHO) places migraine among the world's top 20 
leading causes of disability (15), with an impact that extends far past the suffering individual, 
to the family and community. The WHO report defines the "burden" of migraine to include 
the economic and emotional difficulties that a family experiences as a result of migraine, as 
well as the lost opportunities - the adjustments and compromises that prevent other family 
members from achieving their full potential in work, social relationships and leisure. These 
human aspects of migraine are more difficult to assess and quantify, the report says, but are 
nevertheless vital to fully understanding the implications of the disorder. 
Migraine is estimated to account for 2.0% years of life lost due to a disability in women of all 
ages. In both sexes of all ages, migraine is responsible for 1.4% of total years of life lost due 
to a disability (Table 1). Years of life lost to a disability is defined as years of "healthy" life 
lost in states of less than full health. 
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Table 1 Leading causes of years of life lost due to a disability:  
 
Females All Ages 
 
% Total 
1   Unipolar depressive disorders 14 
2   Iron-deficiency anemia  4.9 
3   Hearing loss, adult onset 4.2 
4   Osteoarthritis 3.5 
5   Chronic obstructive pulmonary disease 2.9 
6   Schizophrenia 2.7 
7   Bipolar affective disorder 2.4 
8   Falls  2.3 
9   Alzheimer's and other dementias 2.2 
10   Obstructed labour  2.1 
11   Cataracts 2.0 
12   Migraine 2.0 
13   Congenital abnormalities 1.9 
14   Asthma 1.8 
15   Perinatal conditions 1.8 
16   Chlamydia 1.8 
17   Cerebrovascular disease 1.8 
18   Protein-energy malnutrition 1.6 
19   Abortion 1.6 
20   Panic disorder 1.6 
 
 
The World Health Organization (WHO) recognition of migraine as a major global disorder, 
therefore, is a major step toward relieving the burden of headache around the world. People 
with migraine score highly on scales of general physical and mental-ill health. According to 
the WHO disability assessment, the disability of a day with severe migraine is in the highest 
disability category, the same disability category than quadriplegia. Despite this, both the 
public and the majority of healthcare professionals tend to perceive headache as a minor or 
trivial complaint. As a result, the physical, emotional, social and economic burdens of 
headache are poorly acknowledged in comparison with those of other, less prevalent, 
neurological disorders (16). 
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In a health economic report on the (17) by the European Brain Council (EBC), migraine came 
out as the most costly of the purely neurological disorders. Data were available only for 
migraine, but there were indications that other headaches could result in as high costs as 
migraine. 
There is a lack of worldwide studies on the different headache sub-types. Those carried out 
have employed different methodologies although headache definitions were standardized by 
the International Headache Society in 1988 (18). What is undisputed is that migraine and 
tension-type headache are the most prevalent headache disorders and, both with disabling 
potential, they have the greatest impact on public health.  
Information is needed to achieve greater recognition and transparency. Headache, particularly 
chronic and recurrent headaches are a major liability in the quality of life in Europe. Migraine 
cost alone are estimated in EU-25, Norway, Iceland and Switzerland at 27 billion Euros.  
 
2.2 Studies performed  
After my active participating in the Headache Disorders and Public Health Meeting, called by 
the Department of Mental Health and Substance Dependence, Non-communicable Diseases 
and Mental Health Cluster of the World Health Organization, held at WHO headquarters, 
Geneva, 13-14 March 2000, I decided to initiate a project to allow measuring the impact of 
headache disorders in Europe in a reliable way.  
I collected the official support from all major stakeholders: public bodies, clinicians, 
headache experts, representatives of patients' organization and representatives of scientific 
organizations (European Headache Federation, International Headache Society) and the 
World Health Organization to support my idea which can be followed up in the trilogy of 
studies of my dissertation.  
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In my first study I gathered information for action to know the scale and scope of the 
problem: I did a comprehensive Medline search for population-based studies of headache and 
migraine used the search terms headache epidemiology or migraine epidemiology or 
headache prevalence or migraine prevalence or headache impact or migraine impact or 
migraine burden or headache burden to put together all the existing worldwide evidence of 
the burden attributable to headache. 
References listed in relevant publications were also examined. All identified articles 
were screened for various aspects of methodology and design, and type of content, in order to 
select methodologically adequate studies for collecting prevalence and impact studies in the 
future.  
I my first study I could show that there were important methodological differences and 
unbridgeable various formulae to calculate the burden of headache. This study allowed me to 
detect the gaps and to define the needs for content and for methodology to collect the different 
socio-economic and humanistic areas of headache disorders in a reliable way. 
As I wanted to know the impact attributed to headache disorders, I initiated in my 
second study a national pilot project in Luxembourg, to define and to validate the content for 
a scientific instrument allowing to collect reliable migraine impact data and to validate this 
instrument in a multicultural environment. 
I persuaded the Ministry of Research in Luxembourg to support this project with a 
national research grant allowing my second study to be independent of pharmaceutical 
company financial support.With the support of major stakeholders I put together a 
questionnaire containing primary measures of headache, secondary measures of disability and 
disease management.  
The data were organized into eight major themes: Epidemiology, diagnosis and 
assessment, issues of care of people with headache disorders (use of system, disease 
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management, treatment outcome/ patient satisfaction), impact on lifestyle, impact on society, 
impact on quality of life and comorbidity. To my knowledge such a tool had so far not been 
developed. After approval by the national data protection and the national ethics committees, I 
undertook a validated translation of the content into German, French, English and Portuguese 
and complete validations tests (face content, language validity, test-retest reliability, internal 
consistency, construct validity, comprehensiveness, completion rate and response rate). 
As a result I could proof that this scientific tool in a questionnaire format, called BURMIG, 
was a valid scientific instrument to collect reliable migraine impact data in the multicultural 
environment of the Luxembourgish population. 
In my third study I initiated the first European project to define the content for a 
scientific instrument allowing collecting reliable headache impact data and to validate and to 
implement this instrument in 10 European countries. 
After expert exchange at national and EU level, involvement of the stakeholders 
including health authority structures, practitioners and patients organisations, we adapted the 
BURMIG questionnaire taking into account the raised adaptation issues from the consortium. 
The resulting questionnaire comprised general epidemiology information (age, gender, 
working situation, language) headache criteria, medical consultation habits and given 
diagnosis; socio-economic information and global burden of migraine (work loss, socio-
economic functioning, WHOQoL, a WHO quality of life  assessment questionnaire for 
comparing quality of life of different health conditions, the hospital anxiety and depression 
scale HADS, a validated scales for the evaluation of depression and anxiety as co-morbidities 
of headache, questions about disease management, their outcome, satisfaction and needs of 
treatment and finally questions about the implication of headache on the social environment 
and the social acceptance of the headache disorder. 
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Once approved by the data protection and ethical committees in each of the 7 validation 
countries (France, Italy, Germany, Austria, UK, Luxembourg, Spain), the questionnaires were 
translated according to an approved language validation procedure in the national languages 
A new informatics tool was developed for the data input of the questionnaires at country level 
and then the questionnaires were validated for face content, language validity, test-retest 
reliability, internal consistency, construct validity, comprehension/completion rate and 
response rates in the 7 different countries.  
The content of the questionnaire was adapted according to the results of the statistical 
analysis. We then translated the resulting questionnaire, named EUROLIGHT, according to 
an approved language validation procedure in the 8 European languages (English, French, 
German, Italian, Dutch, Lithuanian, Spanish and Portuguese) and it is actually used as the 
new scientific instrument for collecting impact data on headache disorders in 10 different 
countries representative of the different regions of Europe. The detailed report on the 
development and validation of the Eurolight questionnaire is shown in my study 3.  
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3.1 Abstract 
A recent health economic survey in Europe has suggested that migraine is the most costly 
among the neurological disorders, and several studies also suggest that migraine and other 
disorders lead to widespread suffering, reduction of quality of life, and marked impairment of 
participation, both in work and social activities. The present literature survey was made in 
order to summarize what is known on the subject, as a preparation for an EU-supported study 
to assess the impact in several EU countries with similar methodology and the same research 
instrument.  
    Previous studies have yielded relatively reliable data only for migraine, whereas the 
impact of tension-type headache is virtually unknown or only very incompletely known for 
most dimensions of headache impact. Some data do suggest, however, that this headache may 
be as important from a health economic and a public health perspective as migraine. In future 
studies it is important to get population-based data from various countries relevant for 
estimation of indirect (mostly absenteeism from work and reduced working efficiency when 
having headache) and direct costs (related to medication, consultations, investigations and 
hospitalisations). Also, the impact on ability to get education and participate in the workforce 
is very relevant, as is the impact on love life and family planning. The quality of life of 
headache patients should be measured by validated instruments. To get a complete picture, 
one should also ask about the effect on the life of partners and children, and on the possible 
impact even when headache free (e.g. fear of the next attack).  
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 3.2 Introduction 
For a just and rational distribution of means to health-care services and health related research, 
reliable data on the individual and societal impact of different disorders are crucial. In recent 
years several initiatives have been launched to raise the awareness that headache is not only a 
nuisance for some individuals, but that it entails widespread suffering and loss of 
opportunities for patients and their families, and large cost for the society. The recently 
published report on the prevalence and burden of headache (1) is a premise for the campaign 
“Lifting the burden: The Global Campaign to reduce the burden of headache” (2). In Europe, 
much data on both the economic costs of migraine have been collected and presented in 
connection with the “Cost of Brain Disorders in Europe” project (3), in which migraine is 
treated along with many of the other (neurological and psychiatric) “brain disorders”. The 
Eurolight project (www.eurolight-online.eu) is an initiative supported by the EU aiming to fill 
in the main holes in our knowledge by performing studies on headache prevalence and impact 
in selected European countries (Austria, France, Germany, Italy, Lithuania, the Netherlands, 
Spain, UK). A pilot study is first performed in Luxembourg. The present review of the 
existing literature on both economic and non-economic impact was performed as a 
preparation for the Eurolight study, partly to assess the current state of knowledge, and partly 
to be able to create a questionnaire to measure all the most relevant aspects of headache 
impact. The present study presents the results of this review and a proposition of the main 
dimensions that ought to be covered in the headache impact instrument to be used in the 
Eurolight study. 
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3.3 Economic impact of headache 
 
Headache may have considerable economic consequences, both for the patient and for the 
society as a whole. There are more studies about the societal costs than about the individual 
economic losses of the patients.  
 
3.3.1 Relation to socioeconomic status, education and employment 
In a large Norwegian study (the HUNT study), both migraine and headache in general was 
associated with low socioeconomic status (4) which has also been found in North America (5, 6) 
but not in some smaller European studies (7-11). The question whether this is a consequence  or 
a cause of headache is not satisfactorily answered, but in one Swedish study, half of the 
patients reported a negative influence of migraine on their ability to pursue studies and one 
third a negative influence on their finances (9). In a US study it was found that headache 
patients have somewhat reduced labour force participation (12), but employment status has not 
been found to be related to headache in some European studies (7-13).  
 
3.3.2 Absenteeism from work 
In two relatively old studies, one from Finland in 1979 (14) and one from San Marino in 1986 
(15), 7% of working individuals had been absent from work in the previous year due headache. 
In a Danish study from 1992 (16), 43 % of migraineurs (5% of the population) and 12% of 
TTH patients (9 % of the population) had been absent from work during the last year due to 
headache, i.e. a total of 14 % of the population. In a Swedish study from 2004 (9) 65 % of 
migraineurs reported some degree of absence from either school or work during the last year. 
These data are, however, of relatively limited interest from an economical viewpoint as they 
do not indicate how many days the headache sufferers are away from work.  
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The number of days with work absence due to headache is relatively consistent across 
studies from different countries. In some previous studies it has varied between 2 and 6 days 
per year among headache patients in general (17), and between 1.5 and 4.2 days per year in 
migraineurs (9). A study among migraineurs in Sweden revealed that 35 % were never absent 
from work due to migraine, and 54 % were absent 1-2 days per year (9). Compared to 
headache free individuals, migraine patients in the HUNT study from Norway lost on average 
4.4 workdays per year and persons with non-migrainous headache lost 2.5 workdays per year 
(18).  In the Danish study from Copenhagen (16), the TTH patients who had been absent seem to 
have been as much or more absent from work than the migraine patients, and the number of 
workdays lost due to migraine was 270 and to TTH 820 per 1000 persons per year, i.e. a total 
of 1090 days. In a study from England in 2003 (13), 15% had been absent from work or had 
reduced ability to work due to headaches in the last three months. Per year, headache 
accounted for 1327 missed and 5213 reduced ability days per 1000 workers per year, 
representing 0.5% and 2.0 % of all working days in the adult population, irrespective of 
headache status. This study did not relate absenteeism to different headache diagnoses. In an 
English study from 2003, an estimated 5.7 workdays per year was missed by migraineurs  
working or attending to school (8). This seems to be higher than in France where a diary-based 
registration of absenteeism published in 1999 showed that migraineurs were away from work 
2.18 days per year due to headache (19).  
 
3.3.3 Effectiveness when working with headache 
Working with migraine results in a 35% productivity loss on average according to some 
European studies (20). This figure is, however, largely based on migraineurs’ self-report, which 
may give a too high estimate according to a recent US study from a workplace (21). In this 
study, it was found that the working ability assessed by self-report was much lower than the 
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objectively measured working efficiency (20 vs 8%). The relatively small decline in working 
ability led the authors to conclude that workers with even relatively severe headache find 
creative ways to cope with the pain and maintain standards.  
 
3.3.4 Health economic studies 
For the headache part of the “Cost of Brain Disorders in Europe” project, a literature search 
for studies containing cost data for migraine and other headaches identified 8 European 
studies evaluating the direct or indirect costs of migraine from a societal perspective (20), from 
France (22-23), Germany (24), The Netherlands (25), Spain (20) (26), Sweden (27) and the UK (28-29).  
No studies analysing the cost of TTH or other non-migraineous headaches were found. There 
were large variations in costs across the six European countries where data were available, 
ranging from around €100 per patient per year in Sweden to nearly €900 in Germany. These 
variations are probably mostly due to different methodologies and differences in the year 
when the studies were conducted. An important finding was that the vast majority of total 
costs, between 72% and 98%, were indirect costs, due to lost productivity, either in the form 
of work absence or reduced efficiency levels when working with migraine. Women tended to 
lose more work days than men, but indirect costs were similar due to lower salaries and labour 
force participation amongst women. The direct costs, related to consultation, diagnostic 
investigations, treatments, and hospital admissions accounted for less than 30% of total costs 
in most studies.  
The cost estimate for migraine in the European report was based on an average of the 
most representative cost estimates, from the UK, Germany and France. An average annual 
cost of €585 per migraine patient was estimated for these Western European countries. The 1-
year prevalence of migraine was 14% among adults in Europe according to the review of 
epidemiological studies (1), i.e. 41 million adult Europeans with active migraine. Per patient 
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migraine was the least costly disorder among the brain disorders. However, due to the high 
prevalence, the total cost of migraine was estimated to be €27 billion for whole Europe in 
2004, which was the highest cost among the purely neurological disorders. Many of the 
psychiatric afflictions were even more costly according to this review. It is, however, likely 
that the available cost data in Europe would tend to underestimate the actual costs of 
headache, mainly because no cost data existed on the most common headache type (TTH), but 
also because children and adolescents were not considered, and because cost connected with 
more expensive medication (triptans) were not included, since most cost studies were 
performed before this class of drugs were introduced.  
In a separate paper summarizing the prevalence and cost data for headache in Europe (30) 
a more speculative estimate for the cost of headache, rather than migraine alone, was derived 
by using the results of the Danish (31) and British (32) population-based studies which 
demonstrated that around 1100 to 1300 days per 1000 workers were missed due to headache 
each year. The British study also suggested that the number of days with reduced efficacy was 
around four times higher than the number of days missed. Assuming a reduced efficiency of 
35% when working with headache, and that the direct costs of headache constitute the same 
proportion of the total costs as for migraine, the average total cost per headache patient was 
estimated to be roughly €420 per year (of which €390 would be due to indirect costs and €30 
due to direct medical costs). Since headache in general was found to affect nearly 50 % of 
Europeans, this estimate, if true, would make headache a much more costly disorder than 
migraine alone.  
It is of interest to compare the European cost study (3) with more recent cost studies in 
some individual European countries. In one study from Spain (33) the annual costs of migraine 
was only about 50% of the sum given in the European Cost study for the same country. The 
difference may partly be explained by somewhat lower prevalence figures (12 versus 14 %) 
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for migraine used in the Spanish study, but the main difference may be that this study did not 
employ a bottom-up design, but used published statistics and data to estimate resource use and 
productivity losses, which may have led to an underestimation of some costs. A recent study 
from France (34), restricted to the direct costs in 1999, found that these costs were at least 
twice as high (€ 128) as in the European migraine cost  study (<€60). This study included 
both “strict” migraine (IHS 1.1 and 1.2) and “migraineous disorder” (IHS 1.7, corresponding 
to 1.6 in ICHD-2), which together affected 17% of the population. For the whole country the 
direct costs amounted to more than 1 billion €, which was 0.068% of the gross national 
product. Non-migraineous episodic headache, affecting 9.2% of the population, entailed a 
considerably lower cost of €28.  
It may also be of interest to compare the European studies with one US study using a 
quite different methodology to assess direct costs. In this study, all types of medical care costs 
(not only those related to headache) were derived from the claims records of a large health 
plan, whereas diagnostic status (migraine or not) and comorbid and demographic status was 
ascertained using a telephone interview among members of the health plan (35). Migraineurs 
incurred on average $700 more per year in total medical care costs than the controls. 
Interestingly, this statistically significant difference disappeared when psychiatric comorbidity 
variables (anxiety and depression) were entered into the model. The much higher costs per 
patient in this than in the French study (34) and Spanish study (33) may therefore at least partly 
be due to the differences in cost assessment methodology, indicating that the direct costs 
specifically related to migraine and not to comorbid disorders are most reliably assessed by a 
direct method, questioning patients about use of health-care resources.  
Medication for headache constitutes an important part of the direct costs. In France in 
year 2000, the most frequently used acute medications for migraine were paracetamol, 
salicylates and NSAIDs. Triptans were used by 8 % of migraineurs, and prophylactic 
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treatment was used by 6% (36). In Denmark 26% of migraineurs had used triptans in 2001, 
but less than 5% of those with pure migraine had used prophylactic medication (37).  
 
3.4 %on-economic impact 
From a purely humanitarian perspective, but also from a public health perspective, the pain, 
suffering and disability caused by headaches are as important as the economic consequences. 
In a study performed in young women in 9 Western European countries, 86 % of migraineurs 
stated that their life would have been better if they did not suffer form migraine (38).  A 
German study showed that, on average, patients with migraine or TTH had around one month 
every year affected by headaches (10). The main burden of headache is carried by a minority of 
sufferers, and a Swedish study has shown that 27% of migraine patients had 68% of all 
attacks (9). Three to four % of the European population have headache half of the days or more 
per month (1).  
 
3.5 Disability 
It has been calculated that in the US, 300 000 persons stay in bed each day (24 hours) due to 
headaches (39). A Swedish study has shown that the disability is not only related to the attacks 
since many migraine patients report impairment also between attacks (40). Nine % of patients 
report that they have some residual disability since they do not recover completely between 
attacks, and in addition, many patients live in a constant worry about the next attack (9-38).  
In some studies the level of disability due to migraine has been evaluated with the 
Migraine Disability Assessment Scale (MIDAS). With this instrument, days with work 
absence (job or household chores), days with ≥50% reduction in productivity, and days with 
inability to participate in social activities is counted during a 3 month’s period. In France, 
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among those with active migraine 22% (1.5% of the whole population) had grades III or IV 
(moderate or severe disability, indicating 11 days or more during the last 3 months’ period 
when headache affected  work/household chores 50% or more, or leisure activities) (36). 
MIDAS III or IV were about twice as common among migraineurs in one US study (54%) (41), 
as it was in the multinational Latin American study (50 %) (42). Among patients with headache 
in general (both migraine and non-migraineous headache, comprising 70% of the study 
population), 10.3% (7.2% of the population) had MIDAS grade III or IV (13). Comparing the 
percentage  of the general population with MIDAS disability grade III-IV due to migraine in 
France (1.5%) (36) with the percentage with same disability due to headache in general in 
England (7.2 %) (13), it seems that non-migraineous headache cause more disability on a 
population basis than migraine. The HALT (Headache-Attributed Lost Time) index is a close 
derivative of MIDAS (http://www.liftingtheburden.org/  → Resources  → Burden measure) to 
be used for headache burden studies which will be conducted by the by the Lifting The 
Burden Campaign (43). 
In the World Health Organisation (WHO), the preferred measure of disease burden is 
“Disability Adjusted Life Years” (DALYs), which is a sum of the years of life lost (YLL) and 
the years lived with disability (YLDs). The YLDs are determined by the incidence and 
duration of the disorder, and by a disability weight ranging between 0 and 1 (44). Although 
migraine entails no increased mortality (i.e. YLL =0), migraine was number 19 of the leading 
causes of DALYs among women aged 15-44, and with regard to YLDs, it was number 19 for 
both sexes, and number 12 for women, irrespective of age. Using the WHO data for a 
calculation of the burden of “brain disorders” (i.e. the psychiatric and neurological disorders) 
in Europe, the weight of migraine was lower than that of the major psychiatric disorders, 
dementias, stroke and injuries, but higher than that of epilepsy, multiple sclerosis and 
Parkinson’s disease (45).  
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In a recent report on the global prevalence and burden of headache disorders, the burden 
of migraine and TTH were measured in a similar way as the DALYs by combining data on 
prevalence, mean number and duration of headache attacks, and headache intensity, from 
studies containing such information. For the world as a whole, it was demonstrated that TTH 
resulted in a higher population burden (approximately 55 % of total burden) than migraine 
(45 %). The data for Europe indicated an even higher burden due to TTH compared to 
migraine (1). If one uses the European data from this study it can be calculated that the hours 
with migraine headache would add up to between 34 and 100 hours per year, if distributed on 
each adult individual in the population. The data on TTH are too scarce to use for similar 
calculations.  
 
3.6 Studies using validated QoL-instruments 
The SF-36 is a validated instrument to measure quality of life (QoL), containing 8 dimensions. 
One US study (46), recruiting migraine patients from a medication trial, demonstrated that 
migraineurs had lower QoL than the general US population, most marked  for bodily pain, 
physical role limitations and social functioning.  
A Dutch population-based study found that migraine had a negative influence on all a 
dimensions compared to controls. The negative influence on QoL was larger than that of e.g. 
asthma, and it increased with increasing headache frequency (47). Two population-based 
studies from Spain among chronic daily headache sufferers showed a marked negative 
influence, most marked for those with medication overuse, but similar for those with a 
headache of a migraine or a tension type (48). One of these showed that the headache 
frequency may have a greater impact than headache intensity on QoL (48), and the other that 
chronic headache with medication overuse was associated with a decrease in all QoL aspects 
studied with SF-36, most marked for role physical and bodily pain (49). A study from UK 
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showed that migraineurs with high or moderate disability had a marked reduction on all 
dimensions on the SF-36 (50). One Swedish study compared SF-36 results in the two sexes and 
in participants with different pain conditions. There was a gender difference for headache, 
which in men influenced physical function, physical role and bodily pain most, and in women 
vitality, social functioning, emotional functioning and mental health (51). In a French study, 
migraineurs had significantly lower scores than headache free controls on all SF-36 
dimensions, and lower scores on the pain dimension than those with other headaches or with 
TTH (52). 
One study comparing migraineurs in the US and the UK used a shorter QoL instrument, 
the SF-12, which contains a physical and a mental component (53). In both countries, 
migraineurs had lower scores than controls on both components also after adjusting for 
socioeconomic status and for depression. However, in those with both migraine and 
depression, the QoL was significantly reduced in comparison to those who were not depressed.  
In another French study, using a disease-specific QoL instrument called QVM, the QoL 
was found to be lowest among those with chronic headache, intermediate among migraineurs 
and highest among subjects with other forms of episodic headache (54).  
The total burden of headache patients may not only be related to the headache per se, 
but also to comorbid conditions. European population-based studies have demonstrated that 
depression and/or anxiety occur 2-3 times more often among migraineurs than in the general 
population (55-56). Depression adds to the reduction in QoL in migraine (53). This comorbidity 
may be as important for non-migrainous headache (57), but it is not known how this 
comorbidity influences the QoL in other headaches. In addition, it has been found that 
headache is also comorbid with other bodily pain, both in Finnish children (58) and Norwegian 
adults (59).  
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3.7 Family impact of migraine 
Migraine also affects the patients’ spouses and children. In a population-based Swedish study 
(9), the % of migraine sufferers who reported a negative impact of migraine was 76% for 
attendance to work, 67% for family situation, 59% for leisure time, 48% for pursuing studies, 
46% for sexual life, 37 % for their social position, 31% for love, 30% for their financial 
situation, 27% for making a career, and 11% for making friends.  
One study has measured the impact on the family in two population samples of similar 
size in US and UK (60). The impact was very similar in both countries. More than 60 % of 
patients reported a marked impact on the ability to do household chores because of their 
migraine during the past 3 months, and it was markedly reduced also in 20 % of the patients’ 
partners. Almost 46 % of patients, and 24 % of partners had missed days of family or social 
activities due to the proband’s migraine, and 16% of patients and 12 % of partners had 
avoided making plans for family or social activities due to the proband’s migraine.  As to the 
impact on the children of patients, more than 60 % stated that it had a moderate to marked 
influence on the relation with their children, 40% stated that they would have been a better 
guardian or parent without migraine, more than 10% stated that their children had missed 
school, and 10 % that their children had been late to school because of their headache. Fourty 
six % stated that they would have been a better partner without headaches, and 5% stated that 
they had had fewer children because of headache, 0.4% that they had avoided having children, 
and 15% that they had avoided oral contraception. Compared with a control group, the 
partners of migraine patients were significantly more dissatisfied with the demands, 
responsibility and duties placed upon them, and with their ability to perform. 
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3.8  Conclusions 
Health economic studies have documented that the costs of headache disorders are huge, the 
costs only for migraine amounting to €27 billion in the EU countries, and the cost for other 
headaches are probably as large. However, better population-based cost studies, are needed to 
assess the cost involved with TTH. Headache sufferers tend to have lower income and 
education, and more of them may be unemployed, but it is still uncertain whether this is true 
for most European countries, and also whether it may be a cause of or an effect of headache. 
It is also amply documented that migraine confers a high degree of disability with more 
forced absence from work and leisure activities, and migraineurs also has a measurably 
reduced quality of life. In addition, there is a marked impact on family life, and headaches 
also put considerable strains on partners and children. A minority of headache sufferers chose 
to have fewer children than they would have had if they had not had headaches.   
Based on the present review we have identified some main domains, summarized in the 
Table 1, which should be covered in order to capture as much as possible of the headache 
burden. The investigations should be performed in population-based samples, and to assess 
the whole burden, it is particularly important that also TTH and not only migraine is included. 
The fact that results on most aspects of headache vary considerably between different 
European countries highlights the need to study several countries with the same methodology 
and instrument. All these methodological aspects will be taken care of in the studies of the 
Eurolight project which are now ongoing. We believe that the results from these studies will 
provide the evidence needed to let headache disorders get the resources for treatment and 
research that they deserve according to the burden that it places on people in Europe.  
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Table 1 The main domains that should be covered in headache burden studies 
 
 
Economic burden  
        Direct cost Medication, consultation, investigations, hospitalisations 
    Indirect costs Workdays lost, 
 Decreased effectiveness when working with headache 
 Lost career and education opportunities 
%on-economic burden  
         Disability MIDAS or HALT 
 Time with disability:  
Headache frequency x duration x intensity/disability 
                Impact outside attacks Residual disability and fear of  next attack 
 Quality of Life SF 36, SF 12, WHOQual etc 
  Family impact Impact on the life of partner and/or children 
   Impact on marriage and love life 
  Impact on family planning and/or contraception 
    Psychiatric complaints Various scales to measure anxiety and/or depression as 
consequent or comorbid disorders 
 
3.9  References 
1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA 
(2007) The global burden of headache: a documentation of headache prevalence and 
disability worldwide. Cephalalgia 27:193-210. 
 
2. Steiner TJ (2004) Lifting the burden: The global campaign against headache. Lancet 
neurology 3:204-205. 
 
3. Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J (2005) Cost of disorders of the 
brain in Europe. Eur J Neurol 12:1-27. 
 
4. Hagen K, Vatten L, Stovner LJ, Zwart JA, Krokstad S, Bovim G (2002) Low socio-
economic status is associated with increased risk of frequent headache: a prospective 
study of 22718 adults in Norway. Cephalalgia 22:672-679 
 33 
5. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of migraine 
headache in the United States. Relation to age, income, race, and other 
sociodemographic factors. JAMA 267:64-69. 
 
6. Breslau N, Davis GC, Andreski P (1991) Migraine, psychiatric disorders, and suicide 
attempts: an epidemiologic study of young adults. Psychiatry research 37:11-23. 
 
7. Rasmussen BK (1992) Migraine and tension-type headache in a general population: 
psychosocial factors. Int J Epidemiol 12:1138-1143. 
 
8. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003) The 
prevalence and disability burden of adult migraine in England and their relationships 
to age, gender and ethnicity. Cephalalgia 23:519-527. 
 
9. Linde M, Dahlöf C (2004) Attitudes and burden of disease among self-considered 
migraineurs--a nation-wide population-based survey in Sweden. Cephalalgia 24:455-
465. 
 
10. Gobel H, Petersen-Braun M, Soyka D (1994) The epidemiology of headache in 
Germany: a nationwide survey of a representative sample on the basis of the headache 
classification of the International Headache Society. Cephalalgia 14:97-106. 
 
11. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and characteristics of 
migraine in a population-based cohort: the GEM study. Neurology 53:537-542. 
 
12. Stang P, Von Korff M, Galer BS (1998) Reduced labor force participation among 
primary care patients with headache. J Gen Intern Med 13:296-302. 
 
13. Boardman HF, Thomas E, Croft PR, Millson DS (2003) Epidemiology of headache in 
an English district. Cephalalgia 23:129-137. 
 
14. Nikiforow R, Hokkanen E (1979) Effects of headache on working ability: a survey of 
an urban and a rural population in Northern Finland. Headache 19:214-218. 
 
15. Benassi G, D'Alessandro R, Lenzi PL, Manzaroli D, Baldrati A, Lugaresi E (1986) 
The economic burden of headache: an epidemiological study in the Republic of San 
Marino. Headache 26:457-459. 
 
16. Rasmussen BK, Jensen R, Olesen J (1992) Impact of headache on sickness absence 
and utilisation of medical services: a Danish population study. J Epidemiol 
Community Health 42:443-446. 
 
17. Stovner LJ, Zwart JA, Hagen K, Terwindt G, Pascual J (2006) Epidemiology of 
headache in Europe. Eur J Neurol 13:333-345. 
 
18. Fiane I, Haugland M, Stovner L, Zwart JA, Bovim G, Hagen K (2006) Sick leave is 
related to frequencies of migraine and non-migrainous headache-The HUNT Study. 
Cephalalgia 26:960-967. 
 34 
19. Michel P, Dartigues JF, Duru G, Moreau J, Salamon R, Henry P (1999) Incremental 
absenteeism due to headaches in migraine: results from the Mig-Access French 
national cohort. Cephalalgia 19:503-510. 
 
20. Berg J (2004) Economic evidence in migraine and other headaches: a review. Eur J 
Health Econom 5:S43-S54. 
 
21. Pransky GS, Berndt E, Finkelstein SN, Verma S, Agrawal A (2005) Performance 
decrements resulting from illness in the workplace: the effect of headaches. J Occup 
Environ Med 47:34-40. 
 
22. Michel P, Auray J, Chicoye A, Dartigues J, Lamure D, Duru G, Henry P, Salamon R 
(1993) Prise en charge des migraineux en France: Coût et recours aux soins. J Econ 
Med 11:71-80. 
 
23. Auray JP (2006) Impact socio-economique de la migraine et des cephalees en France. 
CNS Drugs 20 Spec no.1:37-46. 
 
24. Neubauer G, Uljaky R (2002) Migraine-a disease and its costs. Pharm Unserer Zeit 
31:494-497. 
 
25. van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF (1995) 
Societal perspective on the burden of migraine in The Netherlands. 
Pharmacoeconomics 7:170-179. 
 
26. Lainez MJA, Monzon MJ: The socioeconomic impact of migraine in Spain. In 
Reducing the burden of headache. Oxford: Oxford University Press; 2003:255-259. 
 
27. Björk S, Roos P: Economic aspects of migraine in Sweden. In Working paper no8 
Institute for Health Economics, Lund. 1991:5-24. 
 
28. Blau N, Drummond M: Migraine. London: Office of Health Economics; 1991:26-30. 
 
29. Cull R, Wells N (1992) The economic cost of migraine. Br J Med Econ 2:103-115. 
 
30. Berg J, Stovner LJ (2005) Cost of migraine and other headaches in Europe. Eur J 
Neurol 12 Suppl 1:59-62. 
 
31. Rasmussen BK, Jensen R, Olesen J (1992) Impact of headache on sickness absence 
and utilisation of medical services: a Danish population study. J Epidemiol 
Community Health 46:443-446. 
 
32. Boardman HF, Thomas E, Croft PR, Millson DS (2003) Epidemiology of headache in 
an English district. Cephalalgia 23:129-137. 
 
33. Badia X, Magaz S, Gutierrez L, Galvan J (2004) The burden of migraine in Spain: 
beyond direct costs. Pharmacoeconomics 22:591-603. 
 
34. Pradalier A, Auray JP, El Hasnaoui A, Alzahouri K, Dartigues JF, Duru G, Henry P, 
Lanteri-Minet M, Lucas C, Chazot G et al (2004) Economic impact of migraine and 
 35 
other episodic headaches in France: data from the GRIM2000 study. 
Pharmacoeconomics 22:985-999. 
 
35. Elston Lafata J, Moon C, Leotta C, Kolodner K, Poisson L, Lipton RB (2004) The 
medical care utilization and costs associated with migraine headache. J Gen Intern 
Med 19:1005-1012. 
 
36. Lucas C, Chaffaut C, Artaz MA, Lantéri-Minet M (2005) FRAMIG 2000: medical and 
therapeutic management of migraine in France. Cephalalgia 25:267-279. 
 
37. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R (2005) Secular Changes in 
Health Care Utilization and Work Absence for Migraine and Tension-type Headache: 
A Population Based Study. Eur J Epidemiol 20:1007-1014. 
 
38. Dueland AN, Leira R, Burke TA, Hillyer EV, Bolge S (2004) The impact of migraine 
on work, family, and leisure among young women -- a multinational study. Curr Med 
Res Opin 20:1595-1604. 
 
39. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine 
in the United States: disability and economic costs. Arch Intern Med 159:813-818. 
 
40. Dahlöf CG, Dimenäs E (1995) Migraine patients experience poorer subjective well-
being/quality of life even between attacks. Cephalalgia 15:31-36. 
 
41. Hamelsky SW, Lipton RB, Stewart WF (2005) An assessment of the burden of 
migraine using the willingness to pay model. Cephalalgia 25:87-100. 
 
42. Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, Estevez E, 
Garcia-Pedroza F, Garrido J, Macias-Islas M et al (2005) Prevalence of migraine in 
Latin America. Headache 45:106-117. 
 
43. Steiner TJ (2005) Lifting the burden: the global campaign to reduce the burden of 
headache worldwide. J Headache Pain 6:373-377. 
 
44. Leonardi M, Steiner TJ, Scher AT, Lipton RB (2005) The global burden of migraine: 
measuring disability in headache disorders with WHO's Classification of Functioning, 
Disability and Health (ICF). J Headache Pain 6:429-440. 
 
45. Olesen J, Leonardi M (2003) The burden of brain diseases in Europe. Eur J Neurol 
10:471-477. 
 
46. Osterhaus JT, Townsend RJ, Gandek B, Ware JE (1994) Measuring the functional 
status and well-being of patients with migraine headache. Headache 34:337-343. 
 
47. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ (2000) 
The impact of migraine on quality of life in the general population: the GEM study. 
Neurology 55:624-629. 
 
48. Guitera V, Muñoz P, Castillo J, Pascual J (2002) Quality of life in chronic daily 
headache: a study in a general population. Neurology 58:1062-1065. 
 36 
49. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J (2004) Chronic daily headache 
with analgesic overuse: epidemiology and impact on quality of life. Neurology 
62:1338-1342. 
 
50. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) 
Migraine headache disability and health-related quality-of-life: a population-based 
case-control study from England. Cephalalgia 23:441-450. 
 
51. Bingefors K, Isacson D (2004) Epidemiology, co-morbidity, and impact on health-
related quality of life of self-reported headache and musculoskeletal pain--a gender 
perspective. Eur J Pain 8:435-450. 
 
52. Michel P, Dartigues JF, Lindoulsi A, Henry P (1997) Loss of productivity and quality 
of life in migraine sufferers among French workers: results from the GAZEL cohort. 
Headache 37:71-78. 
 
53. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, 
quality of life, and depression: a population-based case-control study. Neurology 
55:629-635. 
 
54. Duru G, Auray JP, Gaudin AF, Dartigues JF, Henry P, Lantéri-Minet M, Lucas C, 
Pradalier A, Chazot G, Hasnaoui AE (2004) Impact of headache on quality of life in a 
general population survey in France (GRIM2000 Study). Headache 44:571-580. 
 
55. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000) Migraine, 
quality of life, and depression: a population-based case-control study. Neurology 
55:629-635. 
56. Kececi H, Dener S, Analan E (2003) Co-morbidity of migraine and major depression 
in the Turkish population. Cephalalgia 23:271-275 
 
 
57. Zwart JA, Dyb G, Hagen K, Odegard KJ, Dahl AA, Bovim G, Stovner LJ (2003) 
Depression and anxiety disorders associated with headache frequency. The Nord-
Trondelag Health Study. Eur J Neurol 20:147-152. 
 
58. Anttila P, Metsahonkala L, Mikkelsson M, Helenius H, Sillanpaa M (2001) 
Comorbidity of other pains in schoolchildren with migraine or nonmigrainous 
headache. J Pediatr 138:176-180. 
 
59. Hagen K, Einarsen C, Zwart JA, Svebak S, Bovim G (2002) The co-occurrence of 
headache and musculoskeletal symptoms amongst 51 050 adults in Norway. Eur J 
Neurol 9:527-533. 
 
60. Lipton RB, Bigal ME, Kolodner K, Stewart WF, Liberman JN, Steiner TJ (2003) The 
family impact of migraine: population-based studies in the USA and UK. Cephalalgia 
23:429-440. 
 
 
 37 
 
 
 
 
4  Development of a self-reporting questionnaire, 
BURMIG, to evaluate the burden of migraine 
 
 
Colette Andrée 1,2*, Michel Vaillant 1*, Christelle Rott 1, Zaza Katsarava 3, Peter S. Sándor 4 
 
1 Centre d’Etudes en Santé, Centre de Recherche Public – Santé, Luxembourg, Luxembourg 
2 Department of Pharmaceutical Sciences, University of Basle, Switzerland 
3 Department of Neurology, University of Essen Germany  
4 Department of Neurology, University Hospital, Zurich, Switzerland 
 
* These authors contributed equally to the work. 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
4.1 Abstract 
We developed a 77-item-self reporting questionnaire to assess the burden of migraine 
(BURMIG), including headache characteristics, migraine associated disability, comorbidities, 
management, and the consequences on the patients’ lives. We translated BURMIG into 4 
languages (French, Portuguese, German and English) and tested it in 130 headache patients 
(20 pain clinic, 17 primary care and 93 general public) in Luxembourg. We performed a 
linguistic and a face-content validation and tested the questionnaire for its comprehensiveness, 
internal consistency and for its retest-reliability at an interval of one month (completion rates 
were 79.6%, and 76,4%, for test and retest, respectively). Retest-reliability for the different 
parts of the questionnaire varied between 0.6 to 1.0 (Kappa coefficient), with an 
intracorrelation coefficient of 0.7–1.0. The internal consistency was between 0.74 to 0.91 
(Cronbach’s alpha).   
The questionnaire BURMIG is suitable to evaluate the burden of migraine and can be 
used in English, German, French and Portuguese.  . 
 
4.2 Background 
Migraine is a common and disabling neurobiological disorder (1) which is under-recognized 
and under-treated (2, 3). It imposes a substantial health burden, with nearly all migraine 
sufferers experiencing impairment of social activities and of work capacity (4, 5). The World 
Health Report 2002 (3) ranks migraine as number 12 in women and number 19 in both genders 
amongst all causes of disability in the world. In spite of this, it is estimated that only about 
50% of migraine patients are diagnosed and therefore treated adequately (6-10). There are a few 
validated questionnaires such as the ID migraine to diagnose migraine, and the migraine 
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disability assessment score (MIDAS) to assess disability in the last three months, but there is 
no comprehensive questionnaire to assess migraine associated burden.  
The physical and emotional impact of migraine on individual sufferers, their care-takers, 
family and colleagues is poorly acknowledged and this is true as well for the social and 
economic burden of migraine on society in comparison with those of other, less prevalent, 
neurological disorders (9, 11-13).  
We aimed to develop and validate a questionnaire to assess the burden of migraine after 
having translated it into the main languages in order to use it in subsequent studies in different 
linguistic populations. 
 
4.3 Methods 
 
4.3.1 Questionnaire  
We designed a questionnaire combining elements from established questionnaires and added 
further questions concerned with disease management and social consequences of headache. 
Priority areas for the questionnaire were defined with joint support from NGO’S (Swiss 
Migraine Trust Foundation, Migraine Action Association UK, Switzerland and Luxembourg), 
several international headache experts (see acknowledgements) and the Luxembourg Ministry 
of Health. Ethics committee approval for the study was obtained from the National Ethic and 
Research Board of Luxembourg.  
The resulting questionnaire contains 77 items, 17% of them are open questions. In the 
first part, the respondents are asked for biographical details such as age, gender, their most 
spoken language and their employment status. For the purpose of migraine diagnosis, the 
questions from “ID migraine” (14) are included. Specific information on headache, such as age 
of onset, the average number of headache days per month during the last 3 months and 
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symptoms before and after the headaches are gathered as well as information on general 
health, and previous and current disorders using items from the World Health Organization 
Disability Assessment Schedule II (WHODAS II) (15), the Migraine Disability Assessment 
Scale (MIDAS) (16) and the Patient Health Questionnaire-9 (PHQ-9) (17). Participants are asked 
about the influence of headaches on their job and family life as well as whether they had ever 
consulted medical doctors, about the diagnosis that was made and about the medication that 
had been prescribed. Psychosocial circumstances having worsened the headaches, limitations 
in social activities, conceptions of headache and the need of support from health professionals 
to improve the headaches are also assessed. 
 
4.4 Evaluation of the questionnaire 
The testing of the questionnaire included face, content and language validity; the stability of 
the questionnaire over one month, a period of time during which little or no change is 
expected (Test-retest reliability); the extent to which the questionnaire is able to discriminate 
between respondents with more or less severe disease status (construct validity), and the 
extent to which individual items in a questionnaire correlate with other items relating to the 
particular area of investigation (internal consistency). The respective methodology is detailed 
below.  
 
4.4.1 Study population 
Patients with headache were recruited from primary care centres, pain clinics and lay 
organisations. The idea behind this recruitment was to test the questionnaire in different 
settings. Selection for the primary care setting was done by doctors in general practice from 
the personal acquaintance of the project team. For the pain clinic setting the patients were 
selected from the pain clinic of the Centre Hospitalier de Luxembourg (Central Hospital in 
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Luxembourg). When consulting because of headaches, both of these patient groups were 
asked by their physician to complete the questionnaire. For a third group of headache patients, 
headache sufferers with different employment settings were consecutively recruited by the 
national occupational health service and by a patient organization. 
The samples size needed to investigate internal consistency, construct validity and for 
test-retest reliability was estimated by using the kappa formula (see below). Assuming an 
absolute precision of 0.18 (given the validated parts of the questionnaire), we estimated that 
73 responses to the main questions in the second test would enable a Kappa value of ≥ 0.5 to 
be detected with a power of 0.95 (two-tailed α = 0.05). Thus allowing for a 60% response rate, 
135 subjects were considered necessary.  
 
4.4.2 Face, content and language validity 
Initial content validity was explored through systematic review by experts, and face validity 
was tested by pre-piloting with 23 volunteers. All questions which had not been used before 
in the respective language in validated questionnaires were translated using a forward-
backward method with 2 different native translators. Comprehensiveness was piloted with 
native speaker volunteers. 
 
4.4.3 Test-retest reliability 
Questions were categorized by the amount of change expected, as described previously for the 
development of a comparable questionnaire (18), primarily based on the time frame of the 
question and blinded to the results as follows: ‘no change expected’; ‘change unlikely’; ‘1 
unit change expected’; ‘3 unit change expected’; ‘change likely’.  
The data from the two periods of answering the questionnaire were compared to assess 
test-retest reliability. For categorical data, this was estimated by using agreement measures as 
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percentage agreement, Kappa values, Mac Nemar’s S test and Bowker’s S test. Percentage 
agreement gives an estimate of within-patient agreement. The Kappa coefficient indicates 
when the observed agreement exceeds chance-agreement; a value above 0.6 is generally 
considered as acceptable. The Mac Nemar’s S provide a measure of agreement when used 
between two measures of the same questionnaire in the same patient. The null hypothesis of 
the Bowker’s S test is that the probabilities of cells in the square table satisfy symmetry. It 
was used for r x c tables where r>2 or c>2. For the questions with discrete integer data; 
intraclass correlation coefficient (ICC) was calculated using a 2-way random effects model 
for agreement. 
 
4.4.4 Construct validity 
Comparisons between these samples were made for the total scores of the WHODASII, 
MIDAS and PHQ9.  Comparison between categorical scores of the 3 samples was performed 
by using a chi-square test. Continuous values of the scores were also used for comparison and 
a one way-ANOVA was used with the score as dependent variable. Normality was assessed 
with a Kolmogorov-Smirnov test; if significant, data were log-transformed and analysed if 
normally distributed. Otherwise the Kruskall-Wallis test was used.  
 
4.4.5 Internal consistency/Content:  
Where appropriate, cross-tabulations were used to check for internal consistency. Blocks of 
questions corresponding to ID, WHODASII, MIDAS and PH9 were compared in terms of 
correlations. This was done in order to verify if they measure the same construct in a 
multilingual context and in the newly designed questionnaire. The Cronbach’s alpha 
coefficient was used to explore the overall consistency of the ID, WHODAS II, MIDAS and 
PHQ-9 questionnaires. The larger the overall alpha coefficient, the more likely that items 
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contribute to a reliable scale. A value of 0.70 suggests an acceptable reliability coefficient; 
smaller reliability coefficients are seen as inadequate. A coefficient alpha after deleting each 
variable independently from the scale was calculated to determine how each item reflects the 
reliability of the scale. When the coefficient increases after an item is deleted from the scale, 
one can assume that the item is not correlated highly with other items in the scale. Conversely, 
if the coefficient decreases, it can be assumed that the item is highly correlated with other 
items in the scale.  
 
4.5 Results 
4.5.1 Population and frequency of headache in the samples  
130 questionnaires were completed leading to a response rate of 65% (Fig 1). 
Out of this sample, 15.4% (n=20) were from the Pain clinic, 13.1% (n=17) from the primary 
care centre and 71.5% (n=93) from the lay organisation (Table 1). Fifty-two persons (40%) 
responded in German, 1 (0.8%) in English, 72 (55.4%) in French and 5 (3.8%) in Portuguese. 
Eighty-four percent were women, mean age was 41.9 ± 11.5, the gender distribution was 
significantly different (p=0.03) between centres. There was no statistically significant 
difference in age, age at onset of headaches, work status and diagnosis of migraine between 
the 3 groups. Headache frequencies were unequal between centres (p=0.02) with higher 
headache frequencies in subjects at the pain clinic. In the primary care setting, most 
individuals were in the 4-9 days/month category. In the pain clinic, most of the patients had 
headache on ≥15 days/month. The general public population had a similar profile as the 
primary care setting. 
Out of 130 subjects of the whole population, 28 did not answer all the MIDAS questions 
leading to the unfeasibility to calculation of the total score. Thus 102 subjects only had the 
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total score. When re-running the comparison without the unhealthy subjects, only 10 subjects 
out of the 28 had no total scores. 49 subjects had the total score. 
 
Figure 1 Tests and samples used in the different steps of the BURMIG questionnaire 
validation.  
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Table 1 Socio-demographic and headache characteristics of the validation sample 
 
   Primary 
care 
Pain 
clinic 
General 
public 
All p-
value 
Age Year (mean ± sd)  38 ± 13 39 ± 10 43 ± 11 41 ± 11 0.14 
Gender M/F (%)  0/100 30/70 16/84 16/84 0.03 
Work Status Economic workers (%)  70 75 73 73 0.95 
Diagnosis Migraine 
days/month (%) 
 88 70 76 77  0.45 
       
< 1 (%)  0 0 2 2  
1 to 3 (%)  29 30 21 24  
4 to 9 (%)  35 10 45 38  
10 to 14 (%)  18 15 19 18  
Headache 
frequency 
>15(%)  18 45 12 18 0.02 
Age of onset Year (mean ± sd)  24 ± 10 20 ± 11 20 ± 10 20 ± 10 0.36 
 
 
4.5.2 Completion rates  
Completion rates for the items of the questionnaire varied between 5.83% and 100%. As the 
questionnaire included some questions with more than one possible choice or sub-questions, 
only the principal item was kept to evaluate questions with good completion rates. Thus, 63 % 
questions were found to have completions rates of 90% or more. Questions where there were 
several choices tended to have completion rates around 10%. There was no difference for 
completion rates between genders or language groups. Completion rates of the second 
questionnaire varied from 5.41% to 100% and were very similar to the first questionnaire 
(63% of questions with completion ≥ 90%). 
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4.5.3 Test-retest reliability 
Out of the 130 subjects recruited for the validation process, 91 subjects replied a second 
time to the questionnaire sent one month later. Seventy nine single items (incl. sub-questions) 
were used to assess reliability, excluding open questions; 67.1% of the items (n=53) were 
over an 80% agreement whereas 13.9% (n=11) ranged between 60% and 80% and 19% 
(n=15) were below a 60% agreement. 
The Kappa coefficient ranged from 0.23 to 0.99. Questions categorized as ‘no change 
expected’ (0.86 to 0.99) and ‘change unlikely’ (0.68 to 0.99) showed a good agreement (Table 
2). From the items categorized as ‘1 unit change expected’ or ‘3 unit change expected’ the 
kappa showed values ranging from  0.45 to 0.92, indicating a poor agreement for some 
questions; unsurprisingly, from the items categorized as ‘change likely’ the kappa value 
showed lower values ranging from  0.23 to 0.77. Questions which showed the smallest 
agreement were the items from the WHODAS II, PHQ9 and questions 5 and 6 from the 
MIDAS. 
Table 2 Test –Retest reliability with percentage agreement and Kappa values  
 
 % Agreement Kappa p-value for Kappa 
No change expected 79.12 – 98.90 0.86 – 0.99 <0.0001 
Change unlikely 79.12 – 98.90 0.68 – 0.99 <0.0001 
± 1 unit change expected 90.11 – 96.70 0.45 – 0.92 <0.0001 
± 3 unit change expected 72.53 – 84.62 0.45 <0.0001 
Change likely 54.95 – 89.01 0.23- 0.77 <0.0001 
 
Mac Nemar’s S test showed no significant differences. Only one item was significant 
(p=0.03) with the Bowker’s S test: No agreement was observed for ‘Feeling tired or having 
little energy’ from the question 25 (PHQ9) between the two measures. The intra-class 
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correlation coefficient for quantitative answers is detailed in Table 2. Values were significant 
for questions 15 (from WHODAS II) and 18 (from MIDAS) (Table 3). 
 
Table 3 Test –Retest reliability with McNemar’s coefficient for 2x2 tables, Bowker’s 
coefficient for more than 2 classes variables and Intraclass correlation for continuous 
variables. 
 
 Statistic p-value 
McNemar’s coefficient 0.11 – 3.57 0.74 - 0.06 
Bowker’s coefficient 0 – 10.07 0.03 - 1.00 
Intra-class correlation 0.79 – 0.99 0.04 – 0.92 
 
 
4.5.4 Construct validity 
The mean frequency of headache days was significantly different between the 3 samples 
(Table 5). While few subjects had high headache frequency in the primary care and general 
population samples, a large proportion (45% of subjects) in the pain clinic sample had ≥15 
headache days per month. However, there was no difference between the 3 samples in terms 
of average disability attributed to headaches (MIDAS total score) or of depression (as 
measured by PHQ9). The mean scores of WHODASII, MIDAS and PHQ9 were not different 
between the 3 samples (Table 6) except for a significant pair-wise difference between the pain 
clinic and the general population sample with the MIDAS total score (p<0.05) (Table 4). 
 
Table 4  Internal consistency  
 Raw Standardized 
ID Migraine Screener  0.26 0.26 
WHODAS II Questionnaire 0.80 0.91 
MIDAS Questionnaire  0.68 0.74 
PHQ-9 Questionnaire 0.85 0.84 
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A subanalysis was carried-out after omitting patients (n=71) with headache from the 
general population sample in order to better discriminate WHODASII, MIDAS and PHQ9 
values between levels of headaches. The remaining general population sample (n=22) was 
assumed completely healthy while the pain clinic sample was supposed to be the most 
affected group. Results showed a clear trend (p=0.06) for the mean number of days with 
headaches and the presence of depressive disorder (p=0.09). A highly significant difference 
was observed between the general population sample, the pain clinic and the primary care 
sample for MIDAS scores (p-value=0.0005) but not for the PHQ9 depressive disorder 
estimate (Table 5).  
The mean WHODASII score did not show any significant difference in this subanalysis 
while for MIDAS and PHQ9, total scores were significantly different (Table 6).   
When further analysing pair-wise relationships between the 3 samples, differences (p<0.05) 
were observed between the MIDAS score of the pain clinic sample and the general population 
sample when including all subjects, and also between the PHQ9 scores of the primary care 
and the general population sample (Table 6) when excluding incompletely healthy subjects 
from the general population sample. 
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Table 5  Construct validity for Frequency of headaches, MIDAS, and PH9 categorical scores  
 
  
Whole population sample 
 
Healthy subjects 
 
  Primary care 
Pain  
clinic 
General 
population 
sample ALL 
Chi 
Square 
General 
population 
sample ALL 
Chi 
Square 
          
 
% (mean days per 
month of headaches)
 
Less than 1 day 
 
 
 
0 (0%) 
 
 
 
 
 (0%) 
 
 
 
2 (2.15%) 
 
 
 
2 
   
 
 
1 (4.55%) 
 
 
 
1 
  
 
1 to 3 days 
5 (29.41%) 6 (30%) 20 (21.51%) 31  7 (31.82%) 18  
4 to 9 days 6 (35.29%) 2(10%) 42(45.16%) 50  9(40.91%) 17  
10 to 14 days 3 (17.65%) 3 (15%) 18 (19.35%) 24  4 (18.18%) 10  
>15 days 3 (17.65%) 9 (45%) 11 (11.83%) 23  1 (4.55%) 13  
 
Total 17 (13.08%) 20 (15.38%) 93 (71.54%) 130  0.0238 22 (37.29%) 59  0.0629 
          
 
MIDAS score 
 
Minimal or 
infrequent 
disability 
 
 
 
3 (23.08%) 
 
 
 
  4 (23.53%) 
 
 
 
14 (19.44%) 
 
 
 
  21 
   
 
 
  9 (47.37%) 
 
 
 
16 
  
Mild or 
infrequent 
disability 
0 (0%)   0 (0%) 10 (13.89%)   10    5 (26.32%) 5  
Moderate 
disability 
6 (46.15%)   2 (11.76%) 18 (25%)   26    4 (21.05%) 12  
Severe disability 4 (30.77%) 11 (64.71%) 30 (41.67%)   45    1 (5.26%) 16  
 
Total 13 (12.75%) 17 (16.67%) 72 (70.59%) 102  0.159 19 (38.78%) 49 0.0005 
          
 
De Depressive disorder
 
No 
 
 
 
14 (82.35%) 
 
 
 
17 (85%) 
 
 
 
86 (92.47%) 
 
 
 
117 
   
 
 
22 (100%) 
 
 
 
53 
  
Yes   3 (17.65%)   3 (15%)   7 (7.53%)   13    0 (0%) 6  
 
Total 17 (13.08%) 20 (15.38%) 93 (71.54%) 130  0.3179 22 (37.29%) 59 0.0977  
 
 
Headache days, the MIDAS score as a measure of disability and the presence of depression 
are detailed for the different samples of participants according to their origin. On the right 
hand side of the table, the subset of healthy participants (without headache) in the generation 
population sample is detailed.  
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Table 6  Pairwise differences of WHODASII, MIDAS and PH9 scores between groups  
 
 
General population sample 
 
Without unhealthy subjects 
 
 
 
N 
 
Mean 
 
SD 
 
p-value 
 
N 
 
Mean 
 
SD 
 
p-value 
 
 
 WHODAS-II score12 
 
Primary care 
 
 
 
13 
 
 
 
25.85 
 
 
 
15.15 
 
 
 
0.5752 
 
 
 
13 
 
 
 
25.85 
 
 
 
15.2 
 
 
 
0.3015 
Pain clinic 15 21.3 18.42  15 21.3 18.4  
General population  
sample 
84 24.14 15.09   21 17.59 12.8   
 
MIDAS score 
 
Primary care 
 
 
13 
 
 
22.92 
 
 
22.73 
 
 
0.2588* 
 
 
13 
 
 
22.92 
 
 
22.7 
 
 
0.0039* 
Pain clinic 17 38.47 33.87  17 38.47 33.9  
General population 
sample 
72 22.71 20.84   19 7.37 7.11   
 
Score PHQ-9 
 
Primary care 
 
 
 
17 
 
 
 
9.24 
 
 
 
4.51 
 
 
 
0.219 
 
 
 
17 
 
 
 
9.24 
 
 
 
4.51 
 
 
 
0.0049** 
Pain clinic 20 8.1 5.62  20 8.1 5.62  
General population 
sample 
93 7.53 4.59    22 4.95 2.57    
 
* Significant pairwise difference between pain clinic and general pop at the 5% level (Tukey post-hoc ANOVA 
tests) 
** Significant pairwise difference between primary care and general pop at the 5% level (Tukey post-hoc ANOVA 
tests) 
 
4.5.5 Internal consistency/Content:  
The standardized values of the Cronbach’s alpha to test the consistency of (ID, WHODASII, 
MIDAS and PH9 tested in the new questionnaire were 0.26, 0.91, 0.74 and 0.84, respectively. 
Questions categorized by the amount of change expected and compared between the test and 
the retest time to assess the internal consistency showed a 80% to 100% agreement except for 
open questions where more than 70% change was observed. 
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4.6 Discussion 
We described the development and methodological testing of a self-reporting questionnaire to 
evaluate the burden of migraine in the general population.  
Completion rates for each question were generally good with the vast majority between 
60% and 90%. A small number of questions showed low completion rates which can be 
explained by the fact that they were part of multiple choice questions. Some other questions 
did not have to be answered in all participants since they applied only to subgroups. Questions 
from WHODAS II and PHQ9 showed both, good completion rates, and good reliability. For 
methodological purposes, we had defined the amount of change expected for each question 
before administering the questionnaire. Questions where a change had been expected actually 
showed higher amounts of change and lower reliability. This means, that these items were 
used in an appropriate way and that they can be used as part of a questionnaire on the impact 
and burden of migraine and headaches. The question “Feeling tired or having little energy” 
from PHQ9 was found to have little re-test reliability at one month interval which can be 
explained by the transient character of this item.  
Internal consistency was evaluated independently for each scale tested within in the 
questionnaire. It was found to be excellent for the MIDAS and somewhat smaller for 
questions from WHODASII and PHQ9.  
Construct validity was found to be acceptable when samples were adequately chosen to 
discriminate between levels of headache. However, questions from WHODAS showed a poor 
discrimination between headache patients and the general population. This can be explained 
by the fact that this tool is not specifically designed for headache sufferers. The headache 
specific MIDAS, as expected, showed good discriminative power. 
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4.6.1 Disease Management 
Regarding questions on disease management, agreement ranged from 77% to 98% (except for 
multiple choice questions). Kappa coefficient ranged from 0.68 (0.62 with multiple choice 
questions) to 1.00 which indicates good agreement between the 2 steps.   
The majority of the questions about private and social influence were of the multiple 
choice type and scored poorly in terms of percentage agreement (10-30%), but had a good 
retest reliability (kappa coefficients ranging from 0.52 to 0.97). These questions were 
therefore stable with time and could be used in a large study with a period of recruitment 
lasting a few months. 
 
4.6.2 Changes brought to the final questionnaire 
In the disease management part, two questions on medical doctor consultations were merged 
into one question allowing a better completion. 
In one question on the temporal relation between headache and other problems, in 
addition to “before”, and “after” a third item “during” was added.  
 
4.7 Conclusions 
A new questionnaire, BURMIG, was developed with the aim to estimate the burden of 
migraine. It uses established and previously validated items for diagnosis and  measurement 
of disability and depression. Questions related to disease management and the influence on 
daily living were added. The resulting questionnaire was tested in a sample in the Grand 
Duchy of Luxembourg. Reliability and consistency of BURMIG were found to be comparable 
to previously published questionnaires. Therefore, this tool is suitable to study larger 
populations of headache patients.   
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4.11 Appendix BURMIG questionnaire 
 
Evaluation of the Influence and  Management of Headache and 
Migraine in Luxembourg 
 
 
Please answer the survey questions honestly regarding your own current health. If you are a 
primary caregiver for someone else, such as a parent, you may also participate on their behalf.  
For this questionnaire, it is important that you give an answer to all questions. If you need 
assistance you can call 45.32.13-54 Monday-Thursday 9h00-17h00. 
 
GE%ERAL I%FORMATIO% (please tick the correspondent cases) 
 
 
Question 1:  What is your age: ______________(years)   
 
Question 2: Gender:  male   female 
 
Question 3: What language do you speak at home? (please tick the one you speak mostly  
                    at home): 
 
 Luxembourgish  French  German  Portuguese 
 English  Other :    
 
Question 4:  What is your actual working situation? (Please tick all applicable) 
 
 Full time 
employed 
 
 Self-employed  Retired  Other 
 Part-time 
employed 
 Student/school  Housekeeping/Child care 
 
 
ABOUT HEADACHE 
 
Question 5: At what age did you start getting headaches?   
                          
 _________ (years)  
 
Question 6:  What is the average number of days per month on which you suffered 
from headaches during the last 3 months: 
 
 less than 1 day/month         1-3 days/month   4-9 days/month  
 10-14 days/month   15 or more days/month   
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Question 7: Think about (the last 3 months): 
 
- Are you nauseated or sick to your stomach when you have a headache?  
 
   Yes        No 
 
- Does light bother you when you have a headache?  
 
   Yes        No 
 
- Has a headache limited your activities for a day or more?  
 
   Yes        No  
 
Question 8: Do you experience problems before, during or after your headache:  
 
  Yes, before my headache:    duration: _____hours   (e.g. 2 days = 48 hours) 
 
  Yes, during my headache:    duration: _____hours   
 
  Yes, after my headache:     duration: _____hours   
 
  No 
 
If yes please tick which ones:          before         during       after my headache 
 
 Feeling tired                               
 
 Feeling dizzy                              
 
 Speech difficulty                        
 
 Unusual hunger                           
 
 Visual disturbances                     
(Blurred or altered vision) 
 
 Mood changes                            
 
  Swollen limbs                             
 
  Other(s):____________               
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HEALTH A%D LIFE (World Health Organization Disability Assessment Schedule II) 
 
 
Question 9: How do you rate your overall health in the past 30 days ? 
 
 Very good  Good  Moderate  Bad  Very Bad 
 
The questions in this section ask about difficulties due to health conditions. Health conditions 
include diseases or illnesses, other health problems that may be short or long lasting, injuries, 
mental or emotional problems, and problems with alcohol or drugs.  
Think back over the last 30 days and answer these questions thinking about how much 
difficulty you had because of your headache doing the following activities you usually do 
them.  For each question, please tick only one response.   
 
Question 10:  In the last 30 days, how much difficulty did you have in: 
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Standing for long periods such as 30 minutes ?      
Taking care of your household responsibilities?      
Learning a new task, for example, learning how to get to a 
new place? 
     
How much of a problem did you have joining in community 
activities (for example, festivities, religious or other) in the 
same way as anyone else can? 
     
How much have you been emotionally affected by your health 
problems? 
     
Concentrating on doing something for ten minutes?      
Walking a long distance such as a kilometre [or equivalent]?      
Washing your whole body?      
Getting dressed?      
Dealing with people you do not know?      
Maintaining a friendship?      
Your day to day work?      
Overall, how much did these difficulties interfere with your 
life? 
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Question 11: Overall, in the past 30 days, how many days were these difficulties 
present? 
 
 Record number of days:    
 
Question 12: In the past 30 days, for how many days were you totally unable to carry 
out your usual activities or work because of any health condition? 
 
 Record number of days:    
 
Question 13: In the past 30 days, not counting the days that you were totally unable, for 
how many days did you cut back or reduce your usual activities or work 
because of any health condition? 
  
 Record number of days:    
 
Please answer the questions 14-19 about ALL the headaches you have had over the last 
three months.  Write the answer on the line next to each question.  
Write zero if you did not do the activity in the last 3 months. 
 
Question 14: On how many days in the last 3 months did you miss work or school 
(because of your headaches)? 
  
 Record number of days:    
 
Question 15: How many days in the last 3 months was your productivity at work or 
school reduced by half or more (because of your headaches)? (Do not 
include days you counted in question 14 where you missed work or school) 
 
 Record number of days:    
 
Question 16: On how many days in the last 3 months did you not do household work 
(because of your headaches)? 
  
 Record number of days:    
 
Question 17: How many days in the last 3 months was your productivity in household 
work reduced by half or more because of your headaches? (Do not include 
days you counted in question 16 where you did not do household work) 
  
 Record number of days:    
 
Question 18: On how many days in the last three months did you miss family, social or 
leisure activities (because of your headaches)? 
 
 Record number of days:    
 
Question 19: On how many days in the last 3 months did you have a headache? (If a 
headache lasted more than 1 day, count each day) 
  
 Record number of days:    
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Question 20: Over the last 2 weeks, how often have you been bothered by any of the 
following problems? 
 
Please answer Question 20 not only in relation to your headache but how you felt in general  
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Little interest or pleasure in doing things      
Feeling down, depressed, or without hope      
Trouble falling/staying asleep, sleeping too much      
Feeling tired or having little energy      
Poor appetite or overeating      
Feeling bad about yourself – or that you are a 
failure or have let yourself or your family down 
   
 
 
Trouble concentrating on things, such as reading 
the newspaper or watching television 
   
 
 
Moving or speaking so slowly that other people 
could have noticed or the opposite – being so 
fidgety or restless that you have been moving 
around a lot more than usual 
   
 
 
Thoughts that you would be better off dead or of 
hurting yourself in some way 
   
 
 
 
 
 
DISEASE MA%AGEME%T 
 
Question 21: Have you consulted a medical doctor for one of the following reasons since 
your headaches started:   
    
 Please tick all that are applicable: 
 
 Head trauma   Hypertension  Sleeping problems 
 
 Depression    Anxiety or Panic disorder  Allergies 
 
 Eating problems   Asthma   Other : ________ 
 
  No other reason   
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Question 22: How many doctors have you already consulted because of your headaches? 
 
 0     1     2     3    4     more 
 
Question 23: If you have already consulted a doctor because of your headaches, did the  
                      doctor tell you what kind of headache you suffer from? 
 
 Yes        No 
 
 If yes, what kind: 
 
 Migraine   Tension   headache  Cluster  Stress 
 
 Neck 
    problems 
 Other   I do not   
    remember 
 
 
Question 24: How many doctors have you consulted because of your headaches during  
                      the last 12 months? 
 
 0     1     2     3    4     more 
 
If you have not consulted a doctor because of your headaches during the last 12 months, 
why not? 
 
 my headache improved  
 
 my headache did not get better despite the medical consultation more than  
12 months ago 
 
 other reasons:_____________________ 
 
Question 25:  Have you ever been given any tests to investigate your headaches ? 
 
 Yes        No 
 
 If Yes, which one(s): 
  
How many? (number)   year(if possible) 
 
 MRI of my head   ……….……… ……………… 
 
 EEG    ……………… 
 
 CT scan of my head   ……………… 
 
 In depth interview about my headache   ……………… 
 
 Other:………………………………   …….………… 
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Question 26:  Do you currently take any drugs to relieve your headache once it has 
started? 
 
 Yes        No 
 
 If yes, please indicate what drug(s) you are currently taking to relieve  
 your headache: (Please tick all that are applicable, more than one tick  
 possible) 
 
  Aspirine, Aspro, Aspégic   Naramig  Family recipe 
 
  Dafalgan  Panadol     I do not remember 
 
  Ibuprofen, Brufen, Nurofen       Panadol + Codéine  
  
  Imitrex   Primpéran   Motilium 
 
  Maxalt  Relert   Zomig          
    
  Other(s) …………… 
    
Question 27:    Looking back at the last three months, on how many days each month did 
you take medication to relieve your headaches? 
 
 less than 1 day/month  1-3 days/month  4-9 days/month 
 
 10-14 days/month   15 days days/month  
 
 
Question 28:  How many different drugs have you ever tried to relieve your headaches? 
 
 None  one  2-4  5-7  more 
 
Question 29:   If there was a drug which would relieve your headaches, how much do 
you think it would change your quality of life? 
 
  no change at all  slight change  
complete new life    
 
Question 30: Do you currently use a treatment (medication on a daily base or 
alternative/complementary therapies) to prevent your headache? 
  
 Yes        No 
 
 If Yes, which one(s):  …………………………… 
 
Question 31: How many different treatments (medication on a daily base or 
alternative/complementary therapies) have you ever tried to prevent you 
from getting a headache:  
 
 none  one  2-4  5-7  more 
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 If applicable, how successful do rate these treatments to prevent you from 
getting a headache 
 
 Treatment: 
  
 ………………..   not at all  a little   fair  very 
 
 ………………..   not at all  a little   fair   very 
 
 ………………..   not at all  a little   fair   very 
 
 ………………..   not at all   a little   fair   very 
 
 
Question 32:   Have you ever controlled or do you currently control your headaches 
using   one of the following self-management techniques? 
 
 Diet/healthy life style   Sports   Food  
                                                                                                supplements 
 
        Meditation/relaxation  Other method(s) of self-   
management__________________ 
 
 None of the above 
 
 If applicable, how successful do rate the methods? 
  
 Method: 
  
 ………………..   not at all  a little   fair         very 
 
 ………………..   not at all  a little   fair          very 
 
 ………………..   not at all  a little   fair          very 
 
 ………………..   not at all   a little   fair          very 
                
Question 33:  Taking into account everything you do to treat your headache, how well do 
you think you control your headache? 
 
 not at all    a little bit  quite well  completely under  
     control 
 
Question 34:   Please tick of the following services those which you would appreciate to 
be present to improve your headache: 
  
Education for the patient      
 
Consultation with a health professional with specialist     
knowledge of headache 
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 Individualized care      
 
Telephone Helpline     
 
 Written information, brochures     
 
Self management courses    
   
Help with medication ‘withdrawel’ and rehabilitation support  
   
Internet website    
   
Self-help group meetings    
  
 Public forum    
   
Information in the press media    
  
Books    
  
Research studies    
  
Other suggestions: …...…………………………………………… 
 
 
PRIVATE A%D SOCIAL IMPACT 
 
Question 35:   Have headaches ever influenced your job situation/career, school choice, 
job choice? 
 
   Yes        No 
 
 If yes, tick all that are applicable: 
 
 Less chance /missed promotion   Had to change my workplace
  
 Restricted my job’s choice      Less opportunity to get a job
  
 Afraid of losing my job      Had to change school    
 
 Lost my job       Bullying 
 
 Could not pass my exams        Reduce my working time    
  
 Other: _____________ 
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Question 36:  At your working place do you encounter situations which worsen your  
                      headache, like: (Skip this question if not applicable) 
 
 Light  
         
 Air conditioning 
 
 Computer screen       
 
 Noise    
 
 Working positions (e.g. uncomfortable or badly positioned chairs, standing 
too long etc.) 
 
 No relaxation facilities or opportunities 
     
 Other: …………………………… 
 
Question 37: When you talk about your headache do you feel that others understand?   
 
 Your family    No     to some extent      Yes 
 
 Your friends    No     to some extent      Yes           
                         
 Your work colleagues   No     to some extent      Yes 
 
 Your employer   No     to some extent  Yes 
 
 Most people know about my headache: 
 
 Yes        No 
 
Question 38: Have headaches ever influenced your family situation/partnership? 
 
   Yes        No 
 
 If yes, tick all that are applicable: 
 
 Arguing      Feeling guilty 
 
 Isolation      Divorce 
 
 Frustration      Breaking up  
 
 Other: ______________ 
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Question 39: Are there any hobbies/social activities which you enjoy doing/participating 
in, but which you had to limit or which you had to give up/could not 
participate in because of headache? 
  
 Yes        No 
 
 If yes, which ones: …………………………… 
…………………………… 
 
Question 40: Do you feel that your social life is constrained because of headache?         
   
   not at all    to some extent   completely 
constrained 
           
Question 41:  Please tick any popular myths or misconception about headache you are 
confronted with: 
 
 None              
 
 Headache just hurts; you should be able to cope with it easily  
  
  
 Headache only affects weak people    
   
 Headache affects people who can’t cope with stress    
   
 Headache is just putting it up, is just all in the mind    
   
 Headache is just an excuse     
 
 Only women get headaches     
 
 Other: …………………………… 
 
 
Thank you for taking the time to fill in this question, we value your views! 
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5.1 Abstract 
We developed a 103-item-self reporting questionnaire to assess the burden of primary 
headache disorders on those affected by them, including headache characteristics, associated 
disability, comorbidities, disease-management and quality of life. We validated the 
questionnaire in 5 languages with 426 participants (131 in UK, 60 in Italy, 107 in Spain, 83 in 
Germany/Austria, and 45 in France).  
After a linguistic and a face-content validation we tested the questionnaire for 
comprehensibility, internal consistency and test-retest reliability at an interval of one month. 
In the different countries, response rates were between 73% and 100%. Test-retest reliability 
varied between -0.27 to 1.0 depending of the nature of the expected agreement. The internal 
consistency was between 0.69 and 0.91. 
The EUROLIGHT questionnaire is suitable to evaluate the burden of primary headache 
disorders, and can be used in English, German, French, Italian and Spanish. 
 
5.2 Background 
Headache disorders, including migraine, are common and disabling (1) but under-recognized 
and under-treated (2, 3). Consequently, they impose a substantial population burden of ill-health. 
It is well documented that migraine impairs work and social activities (4, 5). The World Health 
Report 2001 (3) ranks migraine 12th in women and 19th overall amongst all causes of disability 
in the world. Less is known about other primary headache disorders, but tension-type 
headache (TTH), being more prevalent, may impose an even higher population disability 
burden than migraine (6). Yet this is poorly acknowledged, along with the physical and 
emotional impact of headache on those directly affected, their carers, family and colleagues, 
and the social economic burden of headache. For example, fewer than half of people with 
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migraine are correctly diagnosed, a prerequisite for receiving adequate treatment (7-11). In 
comparison with other, less prevalent neurological disorders, headache attracts little attention 
and is generally accorded low priority (10, 12-14). 
 The EUROLIGHT project (www.eurolight-online.eu) is an initiative supported by the 
EC Public Health Excecutive Agency and a partnership activity within Lifting The Burden: 
the Global Campaign to Reduce the Burden of Headache Worldwide (www.l-t-b.org). One of 
its main objectives is to gather up-to-date and reliable knowledge of the prevalence and 
impact of migraine, TTH and chronic daily headache across Europe. There is no validated 
instrument for collecting the data that will achieve this. Therefore, the EUROLIGHT steering 
committee has developed the EUROLIGHT questionnaire. 
This instrument is based largely on the BURMIG questionnaire, and has additions from 
instruments developed by Lifting The Burden (15) .The BURMIG questionnaire was developed 
in 2004 for a population-based survey of the burden of migraine in the Grand Duchy of 
Luxembourg. It incorporated previously validated tools for diagnosis, disability assessment 
and recognition of depression, and added questions on disease management and impact on 
quality of life(16). It proved to be consistent and reliable for the Luxembourg population. In 
order to develop the EUROLIGHT questionnaire for use in different European countries, and 
also to encompass other headache disorders, the BURMIG questionnaire was revised. We 
integrated sections to assess disability burden, measure general and disease-specific quality of 
life (QoL), detect anxiety and depression, and enquire into disease management. 
 The aim of the present study was to assess the test-retest reliability and validity of the 
EUROLIGHT questionnaire for use throughout Europe. A pilot validation study in the UK 
was followed by a multi-country study in France, Luxembourg, Germany, Austria, Italy and 
Spain. 
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5.3 Materials and Methods 
 
5. 3.1 Questionnaire development  
The content of the BURMIG questionnaire was reviewed and thoroughly revised by the 
steering committee of the EUROLIGHT project. Priority areas for revision had been defined 
in a pilot study (16) with support from several patient organisations (Migraine Action 
Association UK, Switzerland and Luxembourg), international headache experts (see 
acknowledgements) and the Luxembourg Ministry of Health. The additional or amended 
items were incorporated into the EUROLIGHT questionnaire after a full literature review of 
studies on headache burden (17).  
The final EUROLIGHT questionnaire (see appendix) contains 103 items, 7% of which 
are open questions, 15% numeric questions (ie, requesting a number for answer) and 78% 
categorical (requesting the respondent to place a tick in a box). The first section is 
biographical (age, gender, language and employment). Next are screening questions for 
headache (life-time and 1-year prevalence), followed by a section on chronic daily headache. 
The following questions diagnose the headache that the patient considers to be the most 
bothersome (if more than one headache type is identified). This approach recognised the 
virtual impossibility of accurately diagnosing, by self-administered questionnaire, more than 
one headache type in the same individual. The diagnostic questions, for migraine and TTH, 
were based on the criteria of the International Classification of Headache Disorders, 2nd 
edition (ICHD-II) (18). Further questions relate to age at onset and frequency of headache 
during the previous 3 months. This section is followed by questions about headache yesterday 
(point prevalence), and then by sections on the use of health-care resources (medicines, 
investigations, consultations, etc) and the impact of headache on work, family life and social 
activities (including the Headache-Attributed Lost Time (HALT) Index (19)), both for those 
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with headache and for their household partners. A set of questions determined body mass 
index (BMI), a risk factor, if high, for frequent headache. Finally, there were questions on 
general health derived from the World Health Organization Quality of Life bref (WHOQOL -
Bref) (20) and the Hospital Anxiety and Depression Scale (HADS) (21). 
 
5.4 Evaluation of the questionnaire 
The EUROLIGHT questionnaire was assessed for face, content and language validity; for 
test-retest reliability over one month, a period of time during which little or no change in the 
respondent’s headache is expected; for the extent to which it could discriminate between 
respondents with more or less severe disease (construct validity); and for the extent to which 
individual items correlated with other items relating to the particular area of enquiry (internal 
consistency). The respective methods are detailed below.  
All parts of the study conformed to the ethical standards described in the Declaration of 
Helsinki. Ethics committee approval was obtained from the National Ethics and Research 
Board of Luxembourg. 
 
5.4.1 Study population 
People with headache were recruited by different means in five countries. In England, they 
were recruited from the members of Migraine Action UK. In France, consecutive patients 
were recruited in the Department of Evaluation and Treatment of Pain within the 
Neurosciences Clinic, University Hospital, Nice. In Luxembourg, people with headache were 
recruited from the French-speaking employees of CRP-Santé by email. The subjects from 
Luxembourg and France participated in the evaluation of construct validity. The sample from 
Germany was derived from an existing data bank of the German Headache Consortium, 
University Hospital of Essen, a population-based cohort including people with and without 
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headache. In Austria, consecutive patients were recruited in the Department of Neurology and 
Pain Medicine, Konventhospital Barmherzige Brüder, Linz; healthy subjects were enrolled 
from the personnel working at the hospital and their families. In Italy, 50% of subjects with 
headache came from the waiting list of the Applied Neurological Research Centre of the C 
Mondino Foundation and 50% were members of the headache patient organization, AI.Ce. 
Healthy subjects were enrolled from the staff of the research centre. In Spain, respondents 
with or without headache were recruited from people attending general practitioners for other 
reasons than headache. 
 
5.4.2 Face, content and language validity 
Initial content validity was explored through systematic review by experts, and face validity 
was tested by pre-piloting with 23 volunteers. All questions not used previously in validated 
questionnaires in a particular language were forward-and-back translated by two native 
translators, with reconciliation by a bilingual headache expert. Comprehensibility was tested 
by native language-speaking volunteers. 
 
5.4.3 Test-retest reliability 
Questions were categorized by the amount of change expected within the relevant time frame, 
as described previously for the development of a comparable questionnaire (22), as follows: 
“no change expected”; “change unlikely”; “up to 1 unit change expected”; “up to 2 units 
change expected”; “up to 3 units change expected”.. Respondents in this study completed the 
questionnaire twice, the second time after an interval of one month. At retest they were 
blinded (beyond what they might have recalled) to their responses on the first occasion.  
 To assess test-retest reliability, the two sets of answers were compared. For categorical 
data, agreement measures were the percentage agreement rate, Kappa values, McNemar’s S 
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test and Bowker’s S test. Percentage agreement measures absolute within-patient agreement. 
The Kappa coefficient indicates whether this agreement exceeds what might be expected by 
chance: a value >0.6 is generally considered acceptable. For the questions with discrete 
integer data, the intraclass correlation coefficient (ICC) was calculated using a 2-way random 
effects model for agreement. 
 
5.4.4 Construct validity and internal consistency 
Construct validity was intended to be assessed partly by comparing headache-free participants 
with headache sufferers and partly by measuring the internal consistency of answers to related 
questions. In the course of this part of the study, it transpired that some participants recruited 
as “healthy” were in fact reporting occasional headaches. Construct validity assessment was 
therefore based on headache frequency rather than presence or absence (low frequency = 0-3 
and high frequency >3 headache-days/month). Comparisons between low-frequency and 
high-frequency headache sufferers were made for the total scores of the WHOQoL, HALT 
index and HADS.  Comparisons between categorical scores of those diagnosed with migraine, 
other episodic headache and chronic daily headache were performed by chi-squared test. 
Continuous scores were compared by one way-ANOVA, with the score as dependent variable. 
Normality was assessed by Kolmogorov-Smirnov test; if this was significant, data were log-
transformed and re-analysed if normally distributed; otherwise the Kruskall-Wallis test was 
used.  
 Where appropriate, cross-tabulations were used to check for internal consistency. Blocks 
of questions corresponding to the ICHD-II criteria, WHOQoL, HALT index and HADS were 
explored for consistency using Cronbach’s alpha coefficient: the larger this coefficient, the 
more likely it was that items contributed consistently to a scale, with a value of >0.70 
suggesting acceptable consistency. Recalculating the alpha coefficient after deleting each 
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question within a set determined how each contributed to the reliability of the scale: when the 
coefficient increased after a question was deleted, its responses were not highly correlated 
with those to other questions in the set; conversely, if the coefficient decreased, they were 
highly correlated.  
 
5.4.5 Sample size calculation 
To our knowledge there is no method to calculate the sample size needed to assess face 
content, language validity, construct validity and internal consistency in a questionnaire 
validation study. Therefore the sample size calculation was based on the test-retest reliability. 
Assuming an absolute Kappa precision of 0.18 (based on parts of the BURMIG questionnaire 
that had been validated previously), we estimated that 73 responses to the main questions in 
the second test would enable a Kappa value of ≥0.5 to be detected with a power of 0.95 (two-
tailed α = 0.05). Thus allowing for a 60% response rate, 135 subjects were considered 
necessary.  
 
5.5 Results 
 
5.5.1 UK Pilot study 
Before translations, the English version of the questionnaire was tested in a pilot study of 200 
members of Migraine Action UK; 136 questionnaires were returned of which five were 
deleted from the database because they were duplicated or incomplete. Thus the response rate 
was 65 %. Of the 131 included respondents, 83 answered a second questionnaire one month 
later, but 10 of these were excluded because incomplete identification the link impossible to 
the previously completed questionnaire. Therefore the response rate for retest was 63%  
(Table 1).  
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Table 1. Socio-demographic and headache variables for the validation samples in different countries 
  UK Italy Spain Germany-
Austria 
France 
  Test Re-test Test Re-test Test Re-test Test Re-test Test Re-test 
Age Year (mean ± 
sd) 
49.9 ± 
11.5 
51.3 ± 
11.3 
38.18 
± 
11.67 
38.18 
± 
11.67 
40.44 
± 
11.11 
40.71 
± 
11.01 
41.10 
± 
11.08 
39.43 
± 
11.69 
50.14 ± 
11.75 
50.98 ± 
11.08 
%  131 83 60 60 107 107 83 61 45 43 
Gender
1 M/F (n) 21/110 17/65 17/42 18/42 28/79 28/76 29/53 19/41 9/35 8/35 
            
Work 
status(%) 
full-time 
earning 
45.9 40.0 68.33 68.33 79.44 78.85 56.25 53.33 68.89 65.12 
 part-time 
earning 
28.7 25.0 5.00 5.00 8.41 8.65 22.50 23.33 6.67 4.65 
 full-time 
student 
2.3 - 16.67 16.67 7.48 8.65 10.00 13..33 4.44 2.33 
 unemployed 
but seeking 
employment 
1.5 3.7 5.00 6.67 0.93 . 2.50 1.67 6.67 11.63 
 unemployed 
and not 
seeking 
employment 
7.0 3.7 5.00 3.33 3.74 3.85 6.25 8.33 13.33 16.28 
 retired 18.6 27.5     2.50 .   
    21.55 
± 4.86 
21.47 
± 4.78 
20.60 
± 3.84  
20.65 
± 3.86 
  19.65 ± 
3.51 
19.78 ± 
3.37 
Age of 
finishing  
education 
Year (mean ± 
sd) 
19.8 ± 
5.5 
20.5 ± 
7.0 
    16.00 
± 1.97 
15.98 
± 2.28 
  
            
Income GBP/year 
(mean ± sd) 
40524 ± 
78018 
37379 
± 
24609 
11.86 13.56 8.05 10.23 28324 
± 
27338 
29617 
± 
26201 
21.21 20.59 
    42.37 38.98 33.33 31.82   24.24 23.53 
Partner (%) 81.5 85.4 33.90 37.29 28.74 23.86 62.65 65.57 18.18 26.47 
    6.78 5.08 11.49 15.91   36.36 29.41 
Headache 
frequency 
days/month 
(%) 
  5.09 5.08 18.39 18.18     
 < 1  1.5% 3.7%     15.38 10.42 70.45 70.73 
 1 to 3  12.2% 17.1% 86.67 86.67 66.36 68.57 50.77 50.00   
 4 to 9  34.3% 33.9%     16.92 27.08   
 10 to 14  25.9% 23.2%     7.69 6.25 2.27 2.56 
 >15 25.9% 23.2% 8.89 9.09 11.90 10.00 9.23 6.25 15.91 12.82 
 
1Not all subjects answered the question about gender 
 
 
 
 
 
 76 
Completion rates were ≥90% for 86% of single questions at both test and retest. Questions 
with <90% completion rate were those related to income, questions from the HALT Index and 
those related to impact on children. One question about the “level of control” over headaches 
seemed especially difficult to answer, with completion rates of 49% and 55% at test and retest. 
A question on preventative medications had three response fields (name of medication and 
how long it had been taken in weeks or months); the first field had completion rates of 45% 
and 40% for test and retest while the two other fields fell below 10%. Questions on 
investigations such as MRI and CT also showed completion rates below 10%.  
 Of the 188 questions and sub-questions of the questionnaire, 79 were analyzed by Kappa 
coefficient, 55 by ICC, 20 by McNemar test and 59 by Bowker S test to evaluate the 
reliability (Error! Reference source not found.). Because of the nature of responses to them, 
and the high likelihood of change between test and retest, the reliability of the open-text-field 
questions could not be quantified. 
 Among the questions categorized as “no change expected”, two of those  analyzed by 
Kappa coefficient were responsible for lowering the rate of agreement (<30%) while all others 
analyzed in this way showed test-retest agreements of 40-100% (Error! Reference source 
not found.). The Kappa coefficient varied from 0.26 to 1, with questions from the HADS 
contributing most (from 0.36 to 0.55) to a low value. For questions with quantitative 
responses, analyzed by ICC, the rate of agreement varied from 1% to 74%, with the extreme 
low value due to a diagnostic question asking the number of days with headache (Appendix, 
question 18). Most of these questions were in the range 20% to 25%. The ICC was good for 
these questions. 
 For the questions categorized as “up to 1 unit change expected”, only a third had 
agreement rates of <60%. Age had the highest value (98%). These questions were also 
associated with low Kappa coefficients: only one quarter of them had coefficients >0.5. 
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 Only two questions were categorized “up to 2 units change expected”; these had 12% 
and 100% agreement rates with Kappa coefficients of 0.16 and 0.66. Six questions were 
categorized “up to 3 units change expected”: one had an agreement rate of 36%, with a Kappa 
coefficient of 0.21, which is not a good result, and 5 HALT Index questions showed 
agreement rates of 25-52 %, with an ICC varying from 0.83 to 0.92, which is a good result. 
 For questions with two response options, McNemar’s S test showed a significant 
difference for one question, which asked whether the respondent had a headache yesterday 
(Appendix, question 32). A change of response to all questions about headache yesterday is 
expected between test and retest. Only three items were significant (p<0.05) on Bowker’s S 
test: no agreement was observed for questions attempting to measure lost work due to 
headache (Appendix, question 36 and 37) and the question about how headache was accepted 
at work (Appendix, question 53). 
 Internal consistency was evaluated independently for the blocks of questions derived 
from WHOQoL, the HALT index and HADS. The standardized values of Cronbach’s alpha 
were, respectively, 0.93, 0.88 and 0.90. 
 Following this pilot study, the phrasing and the response options of some questions were 
modified. In general, however, the pilot study showed that the questionnaire was well 
understood and yielded satisfactory completion rates; therefore, no questions were deleted or 
added. 
 
5.5.2 Validation study in other countries 
The slightly amended questionnaire was translated for validation in the other countries. 
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5.5.2.1 Populations  
The numbers of subjects participating in each country is given in Table 1. There was a female 
preponderance in all countries. Most respondents were full- or part-time employed or self-
employed, while students, unemployed and retired people accounted for 10 to 20%. Average 
age was 40 years except in France where it was 50 years. 
 
5.5.2.2 Response Rates 
Numbers of responders in each country are given in Table 1, varying between 66% and 100%. 
In Spain, one questionnaire was deleted from the database as it was incomplete. 
 
5.5.2.3 Completion rates 
Completion rates for each question were adjusted according to expectation. A rate >100% 
meant that the participant was not expected to answer a particular question but nevertheless 
did: for example, some respondents answered that they had not had headache yesterday, but 
still had taken medicines to relieve headaches on that day. Per country, the percentages of 
respondents with completion rates over 90% were: Germany-Austria: 69%; Spain 75% ; Italy 
65%; France: 82%. 
 Certain questions had low completion rates. For the question on duration of use of 
preventative drugs (Appendix, question 45), the rate was <30% in Italy and <10% in the other 
countries. The questions concerning MRI and CT scans had completion rates <10% in Italy, 
<30% in Spain and <20% in Germany-Austria. The HALT-Index questions had low 
completion rates in France, ranging from 52% to 61%.  
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5.5.2.4 Test-retest reliability 
In Italy, 141 questions (including some sub-questions) were used to assess reliability (open 
questions were excluded, as they could not be quantified). Of these, 42% (n=59) showed 
>80% agreement, 10% (n=14) ranged from 40% to 80% and 48 % (n=66) had <40% 
agreement (Error! Reference source not found.). In Spain, 149 questions were used (again 
including sub-questions and excluding the open questions). Of these, 46% (n=69) had >80% 
agreement, 16 % (n=23) ranged between 40% and 80% and 38 % (n=57) had <40% 
agreement. In Germany-Austria and in France, 116 questions were used (including sub-
questions and excluding open questions), of which 36% (n=42) showed >80% agreement, 
21% (n=24) ranged between 40% and 80% and 43% (n=50) had <40% agreement. 
 Two “no change expected” questions were identified as largely responsible for lowering 
the rate of agreement below 40%. The first (Appendix, question 15) asked for the medication 
usually taken to treat chronic daily headache; some participants may not have understood well 
enough the accompanying text to the question. The second (Appendix, question 56) question 
asked how well subjects were able to control their headache. In this category, two other 
questions had low reliability scores. The first asked for the number of days with headache 
(Appendix, question 18), giving respondents the reply options of “every day” or stating the 
number of “days/month” or “days/year”. The second asked the duration of headache in 
minutes, hours or days (Appendix, question 20).  
 Of “up to 1 unit change expected” questions, 26 out of 48 in Italy had agreement rates of 
<60% (only 11 having Kappa coefficients of >0.5). Corresponding numbers were 29 of 48 in 
Spain, 24 of 46 in Germany-Austria and 22 of 48 in France; in all countries these questions 
accounted for the low Kappa coefficients. The question about investigations e.g MRI and CT . 
(Appendix, question 48) unsurprisingly also had low agreement rates. Questions on the effects 
of headache on education, career and family planning (Appendix, question 50-76), with 4-6  
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Table 2. Test –Retest reliability of questionnaire (percent agreement; Kappa values and IntraClass Correlation Coefficient values for variables of 2 
modalities; McNemar’s coefficient for 2x2 tables and Bowker’s coefficient for variables with more than two response options. 
 
% Agreement Kappa % Agreement Kappa % Agreement Kappa % Agreement Kappa % Agreement Kappa
%o Change Expected 2.-99 0.26 – 1 2. - 100 0.65-1.00 1. – 98 -0.01 – 1.00 2.-97 -0.07 – 1.00 2.-98 -0.06 – 1.00
± 1 unit change expected 1. – 100 -0.03 – 0.95 2. - 100 -1.04 1. – 100 -0.19 – 1.00 2-100 -0.27 – 1.00 2.-100.00 -0.14 – 1.00
± 2 unit change expected 12. - 100 0.16 – 0.66 13 . 13 0.35 10 0.47 33 0.27
± 3 unit change expected 36 0.21 13 0.46 12 0.28 10 - 30 0.17
% Agreement ICC % Agreement ICC % Agreement ICC % Agreement ICC % Agreement ICC
%o Change Expected 1.-73 0.76 - 0.097 3. - 95 0.16-0.99 7. – 86 -0.06 – 0.99 2.-85 0.13-0.99 2.-93 0.72 – 0.99
± 1 unit change expected 98 0.99 100 1 97 0.99 97 0.89 100 0.99
± 2 unit change expected - - 58 - 65 0.60-0.97 55 – 60 0.89 – 0.95 28-38 0.55-0.94 23-33 0.58 – 0.94
± 3 unit change expected 25-52 0.83-0.99 Dez 65 0.83-0.93 8 – 69 0.80 – 0.83 8.-64 0.89-0.99 16-65 0.80 – 0.86
Change likely 1.-31 0.55-0.99 2. - 100 -3.55 1. – 100
-27.15  – 
0.99 2.-100 -3.24 2.-100.00 -6.64 – 0.99
Statistic p-value Statistic p-value Statistic p-value Statistic p-value Statistic p-value Statistic p-value Statistic p-value Statistic p-value Statistic p-value Statistic p-value
Mc%emar’s coefficient - - - - 0-3 1-0.1025 4-14 0.0455-
0.0002
0-4 1-0.0588 - - 0-3 1-0.083 - - 0-2 1-0.1573 4-6 0.0455-
0.0143
Bowker’s coefficient - - - - 0-6 1-0.81 8 0.046 0-9 1-0.5 54.8-64.8 <0.0001 0.3-10 0.95-0.12 31.36-35 <0.0001 0-9 1-0.17 22 0.0012
Intra-class correlation 0.6-1 0.32-0.63 0.89-0.99 0.048-
<0.0001
-3-1 0.42-0.90 0.93-0.97 0.013-
0.034
-27-1 0.061-0.18 0.88 0.046 -2-1 0.87-1 - - -7-1 0.52-0.74 0.84-0.99 0.0004-
0.041
<0.0001
-
Not significant SignificantNot significant Significant
UK
p-value
<0.0001 – 0.0004
<0.0001 – 7894
<0.0001 – 0.0115
0.0002
p-value
0.05-0.80
Significant Not significant Significant
<0.0001-0.66
0.32-0.93
Not significant Significant Not significant
0.0348 – 0.4198
0.0004 – 0.8790
p-value
0.02-0.72
.
0.03-0.69
p-value
0.06 – 0.56
0.1
0.05 – 0.85
0.95
0.14-0.96
0.10-0.01
0.01-1.00
0.12 – 0.28
0.06 – 1.00
0.15-0.21
0.13-0.87
p-value
0.0781 – 0.8118
0.0272
0.0409 – 0.4332
p-value
0.14-1.00
<.0001
p-value
<.0001 – 0091
<.0001 – 0.90
<.0001
<.0001
p-value
<.0001
-
p-value
<.0001 – 0.71
<.0001 – 0.80
0.0096
0.0807
p-value
<0.0001 – 0.0087
France-LuxembourgGermany-Austria
<.0001-0.74
.
SpainItaly
<0.0001 – 0.87
<0.0001
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possible response options, had agreement rates of <10% in Italy. As multiple responses could be 
chosen, completion rate was calculated for each possibility. As a consequence, percentage 
changes were very low for all responses other than “no”. Three questions of the WHOQOL and 
one from the HADS showed significant Bowker S tests in Germany-Austria, Spain and France, 
meaning that there was lack of reliability over time. 
 There was one question with “up to 2 units change expected”, and this had very low 
agreement rates: Italy 13%, Germany-Austria 10% with Kappa=0.47, France 33% with 
Kappa=0.27, Spain PA=13% with Kappa = 0.35. 
Of questions in the category “up to 3 units change expected”, only one had low agreement 
rates: in Italy (3%, Kappa=0.46), Spain (12%, Kappa =0.28) and France (30%, Kappa=0.17). 
However, the poorest agreement was for the HALT index, the reliability of which was measured 
by the ICC associated with the percentage agreement rate: in Italy, 58-65% with ICC = 0.60 to 
0.97; in Spain 90-100 % with ICC = 0.88 to 0.95; in Germany-Austria 28-38% with ICC = 0.55 
to 0.94 and in France 23-36% with ICC = 0.58 to 0.94. 
 
5.5.2.5 Construct validity and internal consistency 
The four populations were relatively similar overall with respect to age, gender and employment 
status. However, there were significant differences in each country between headache sufferers 
and participants without headache (Table 3). Age was higher in the French speaking sample with 
high headache frequency. Males were more frequent amongst the “headache-free” participants, 
except in Italy. There were more employed persons amongst people with headache in Italy and 
Germany-Austria compared with Spain and France-Luxembourg (significantly for France-
Luxembourg).  
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Table 3. Internal consistency of question blocks (WHOQoL, HALT, HADS) (standardized 
values of Cronbach’s alpha) 
 UK Italy Spain 
Germany-
Austria 
France-
Luxembourg 
WHOQoL 0.93 0.86 0.86 0.9 0.82 
HALT index  0.88 0.81 0.86 0.91 0.69 
HADS 0.9 0.88 0.89 0.91 0.78 
 
Internal consistency was evaluated independently for each block of questions derived from 
WHOQoL, HALT index and HADS. The standardized values of Cronbach’s alpha were high in 
all cases, indicating excellent consistency. 
 It is indicative of good construct validity that the mean scores for WHOQoL, HADS overall, 
HADS anxiety (HADS A) and HADS depression (HADS D) were significantly different between 
those with and those without headache in each country. In addition, the HALT index, used to 
compare groups with low and high headache frequencies in France-Luxembourg, showed 
significantly higher scores in the latter. 
 We further investigated construct validity by comparing those with different types of 
headaches (migraine, other episodic headache or chronic daily headache) (Table 5). The mean 
scores of WHOQoL were significantly different between these in each country. The mean HADS, 
HADS-A and HADS D scores were significantly different between these in each country except 
Spain. The mean scores of the HALT index were significantly different in each country except 
France-Luxembourg. 
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Table 4. Construct validity for WHOQoL, HADS and HALT index in relation to headache status.  
* one subject was excluded due to a high score of 261 
 
 
Country Headache No 
headache
ALL p-value
Age Year (mean ± sd) Italy 38.5 ± 10.9 37.4 ± 13.4 38.2 ± 11.7 0.4692
Spain 39.4 ± 10.9 42.9 ± 11.4 40.4 ± 11.1 0.119
Germany and Austria 42.9 ± 9.9 37.8 ± 12.5 41.1 ± 11.1 0.0597
France and Luxembourg 47.8 ± 13.1 37.1 ± 11.8 41.8 ± 13.4 <.0001
Gender M (%) Italy 25 36.8 28.8 0.34
Spain 16.2 48.5 26.2 0.0005
Germany and Austria 26.4 51.7 35.4 0.0219
France and Luxembourg 17.1 37.2 28.3 0.0326
Work Status Economic (%) Italy 73.2 57.9 68.3 0.24
workers Spain 75.7 87.9 79.4 0.1492
Germany and Austria 82.7 71.4 78.8 0.2401
France and Luxembourg 68.3 86.6 78.5 0.0335
WHOQoL (mean ± sd) Italy 27.5 ± 4.6 32.6 ± 3.2 29.1 ± 4.9 <.0001
Spain 28.1 ± 5.2 30.2 ± 4.7 28.8 ± 5.1 0.0382
Germany and Austria 30.3 ± 5.9 34.0 ± 4.6 31.5 ± 5.8 0.012
France and Luxembourg 27.7 ± 5.2 32.2 ± 3.7 30.3 ± 4.9 <.0001
HADS (mean ± sd) Italy 13.3 ± 6.3 4.3 ± 3.7 10.4 ± 7.0 <.0001
Spain 12.5 ± 6.9 8.5 ± 7.0 11.2 ± 7.2 0.0047
Germany and Austria 12.4 ± 7.8 6.1 ± 6.3 10.3 ± 7.9 0.0003
France and Luxembourg 17.4 ± 6.5 11.6 ± 6.5 14.2 ± 7.1 <.0001
HADS Anxiety (mean ± sd) Italy 6.9 ± 3.7 2.4 ± 2.4 5.5 ± 3.9 <.0001
Spain 6.7 ± 4.0 4.1 ± 4.0 5.9 ± 4.2 0.0005
Germany and Austria 7.3 ±4.0 3.4 ± 3.4 5.9 ± 4.2 <.0001
France and Luxembourg 9.9 ± 3.6 7.1 ± 3.7 8.3 ± 3.9 0.0003
HADS Depression (mean ± sd) Italy 6.2 ± 3.6 1.9 ± 1.8 4.8 ± 3.8 <.0001
Spain 5.7 ± 3.8 4.4 ± 3.5 5.3 ± 3.7 0.095
Germany and Austria 5.1 ± 4.6 2.6 ± 3.2 4.3 ± 4.3 0.0091
France and Luxembourg 7.5 ± 3.6 4.7 ± 3.8 5.9 ± 3.9 0.0005
HALT Index (mean ± sd) Italy
Spain
Germany and Austria
France and Luxembourg 28.7 ± 65.7 1.9 ± 3.5 9.5 ± 36.3 <.0001
HALT Index* (mean ± sd) Italy
Spain
Germany and Austria
France and Luxembourg 12.1 ± 14.2 1.9 ± 3.5 4.7 ± 9.0 <.0001
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Table 5. Construct validity for WHOQoL, HADS and HALT in relation to headache diagnoses  
Variable % Mean SD p % Mean SD p % Mean SD p % Mean SD p
WHOQOL others headaches 20 30 3,9 0,0031 47 30 4,7 0,0182 41 32 3,7 0,0041 12 25 5,4 0,0285
migraine 12 30 5,1 25 27 5,3 9 24 7,8 16 30 4,8
chronic daily headaches 15 25 3,7 9 25 3,7 6 28 8,1 11 27 3,4
HADS others headaches 19 9 6,1 0,0118 47 11 6,7 0,5368 44 10 6,7 0,0169 12 23 4,8 0,0038
migraine 12 12 7,7 24 12 6,8 10 18 6,7 15 16 6,3
chronic daily headaches 16 16 4,7 8 15 8,6 6 16 11,0 12 18 4,9
HADS_A others headaches 20 5 3,7 0,0293 47 6 4,3 0,3914 45 6 3,8 0,0738 12 12 3,1 0,0372
migraine 12 7 4,6 25 6 3,6 10 9 3,3 16 9 3,4
chronic daily headaches 16 8 2,7 8 8 3,8 6 8 5,5 12 10 3,3
HADS_D others headaches 19 4 2,8 0,0122 47 5 3,4 0,6366 44 4 3,4 0,013 13 10 2,4 0,0047
migraine 12 6 4,2 24 6 3,6 10 8 4,3 16 6 3,3
chronic daily headaches 16 8 3,2 9 7 5,2 6 8 7,4 13 8 2,8
HALT others headaches 17 16 34,2 0,0004 35 8 13,7 <0.0001 24 2 3,2 0,0003 4 27 18,7 0,121
migraine 12 19 11,3 23 16 16,9 7 35 54,8 6 8 5,4
chronic daily headaches 16 67 61,6 9 50 34,3 2 72 53,7 4 68 128,9
Spain FranceItaly Germany-Austria
 
HADS: Hospital Anxiety and Depression scale 
HADS_A: HADS-Anxiety, HADS_D: HADS-Depression 
 
5.6 Discussion 
This paper describes the development and testing of the EUROLIGHT questionnaire to evaluate 
the burden of headache disorders in different European populations. The questionnaire originated 
in the BURMIG questionnaire, and was revised after a systematic literature review and 
discussions among headache experts and lay persons in the EUROLIGHT steering committee. 
The English version was tested in a UK pilot study, and after some minor amendments the 
resulting questionnaire was translated and tested in a German version in Austria and Germany, a 
French version in France and Luxembourg, a Spanish version in Spain and an Italian version in 
Italy.  
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 As to test-retest reliability, good response rates were achieved, and completion rates for 
each question were generally good with the majority (65% to 80%) above 90%. A small number 
of questions required modification in the light of likely causes for low completion rates. Sub-
questions asking for the total number of days or occasions were deleted as they were not 
completed by respondents. Questions with text field for respondents to fill in also had to be 
avoided. Questions from WHOQoL and HADS showed good completion rates, and good 
reliability. This was not the case for the HALT index, especially in France.  
 For methodological purposes, we had defined the amount of change expected for each 
question before administering the questionnaire. Questions where a change had been expected did 
show higher amounts of change, indicating that these items were understood correctly and 
therefore can be used as part of the EUROLIGHT questionnaire.  
 The reliability coefficients also showed convincing results. Kappa and ICC showed values 
above the defined significance threshold (see Methods). However a small number of questions 
needed to be modified to increase the reliability of the questionnaire.  
 Internal consistency was found to be excellent for WHOQoL, HADS, HADS A, HADS D 
and the HALT index. 
 Construct validity was found to be acceptable in different countries as the relevant 
questions were able to discriminate between groups of respondents with different headache 
frequencies and diagnoses. The tools WHOQoL, HADS and HALT index used within the 
questionnaire discriminated well between those with and those without headache. In headache 
sufferers alone, questions from the HADS showed a low discrimination between headache types, 
which is unsurprising, as comorbidity is known to differ little between headache type but more 
according to headache frequency (23-25). The headache-specific tool HALT showed good 
discriminative power in most counties, although not in France and Luxembourg. 
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 For questions on disease management, test-retest agreements ranged from 77% to 98% 
(except for questions with multiple response options). Kappa coefficients ranged from 0.68 (0.62 
for questions with multiple response options) to 1.00, which indicates good agreement. 
 The majority of questions about private and social impact were of the type with several 
response options, and these scored poorly in terms of agreement rate (10-30%) but had a good 
test-retest reliability (Kappa coefficients ranging from 0.52 to 0.97). As the responses to these 
questions were stable over time we believe that they truly reflected the headache impact on 
patients’ lives over a certain period and not only how they perceived it on that day.  
 It is a weakness in the development of the questionnaire that the diagnostic questions have 
not yet been validated against a gold standard method for diagnosing headaches (interview and 
examination by a headache expert), which is mandatory when diagnostic accuracy is of 
paramount importance (26). Diagnostic validation should be done in the population to be studied 
and, since the present study was mostly performed among headache patients who had already 
been diagnosed and treated, this was not done. When the population-based studies with the 
EUROLIGHT questionnaire are performed, some sort of validation in the different countries is 
planned in order to assess the diagnostic precision of the questionnaire.  
 
5.7 Conclusion 
The EUROLIGHT questionnaire was developed in order to estimate the burden of headache 
disorders in Europe. Established and recently validated tools for diagnosis, disability and 
comorbidity were supplemented with more detailed questions on disease management and impact 
on school, work, family, social life and quality of life. The resulting questionnaire was tested in 
UK, Italy, Spain, Germany, Austria, France and partly in the Grand Duchy of Luxembourg. 
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Reliability and consistency were found to be comparable to those of previously published 
questionnaires (16, 22). The validation process resulted in relatively minor changes.  
We believe the final EUROLIGHT questionnaire, at least in the 5 languages that have been 
tested, will give a reliable and valid picture of the impact and burden of primary headache 
disorders in European populations. Since headache is a considerable burden for people 
everywhere, we hope that the questionnaire can be adapted for use in many other countries and 
cultures.  
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Appendix: EUROLIGHT questionnaire 
 
  
Lifting The Burden 
The Global Campaign to Reduce the Burden of Headache 
Worldwide 
 
A partnership in action between the World Health Organization, 
World Headache Alliance, International Headache Society and 
European Headache Federation 
Impact of headache 
questionnaire - Eurolight 
To be answered by headache sufferers  
A%D  
by people who do not suffer from headaches 
 
Eurolight is a partnership activity within Lifting The Burden: WHO’s Global Campaign to 
Reduce the Burden of Headache Worldwide, supported by a grant of the European Union 
Executive Agency for Health and Consumers and promoted by the Centre of Public Health 
Research in Luxembourg. 
 
Center identifier 
 
 
 
 
                       ______________________ 
 
Your date of birth  
 
Day___ /month____ /year___ 
 
Thank you for answering the following questions. Please begin by entering today’s date, 
and then answer all questions on this day. 
 
1  
Please enter today’s date 
 
Day___ /month____ /year___ 
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2  
What is your age? 
 
_____ years 
3  
What is your gender? 
(please tick one box) 
 
male   female  
Social situation questions 
 
Which of these is closest to your personal situation?  
(please tick one box only) 
 
employed or self-employed  
homemaker or housewife   
student  
unemployed  
4 
retired  
Are you now married or living with a household partner? (please tick one box) 
 5 
no  yes  
What is your total net household income per year? 
(please tick one box) 
 
less than 18 000 €   
between 18 000€ and 29 999 €    
between 30 000 € and 41 999 €    
between 42 000 € and 59 999 €    
6 
more than 59 999 €   
How old were you when you left full-time education? 
7 
________years still in process  
What is your native language (the language you first learned to speak)? 
8 
 
enter name of language: _______________ 
 
What language do you usually speak in your own home? 
9 
 
enter name of language: _______________ 
 
Screen questions 
 
Have you ever had a headache? (please tick one box) 
no  (if no, go directly to question 74) 10 
yes    
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Have you had a headache during the last year? (please tick one box) 
no  (if no, go directly to question 74) 
11 
yes    
 
During the last 30 days, on how many of these days did you have a headache? 
(please enter number of days between 0 and 30) 
12 
 
______ days    If you answered 15 or more, please continue with questions 13-16. 
                        Otherwise, go directly to question 17. 
 
 
Daily headache questions 
You have said that you had headache on 15 or more days in the last month. 
Please think about these headaches. 
 
 
How long, during each day, do these headaches usually last? 
(please enter the number of minutes or hours) 13 
 
_____ min        or        _____ hr 
 
 
Do you usually take any medication to treat these headaches? (please tick one box) 
(please note that this question is about treatment to relieve the headache, not daily 
treatment to prevent headache) 
 
no  (if no, go directly to question 17) 
14 
yes    
 
What medications do you use most to treat these headaches? 
(please note that this question is only about treatment to relieve headache) 
(if you use no medications at all for these headaches, please tick the box) 
none   
name the most-used medications: _________________________ 
15 
                                                          
 
Altogether, on how many days in the last 30 days did you take these medications? 
(please enter number of days between 0 and 30) 16 
  
______ days 
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“Most bothersome headache” questions 
These are questions on the headaches that interfere most with your life. These headaches may be 
the same as the headaches you have just described, or they may be different headaches if you 
have more than one type of headache. 
Please think about your headaches. Do you think they are all of one type, or are they of 
more than one type?  (please tick one box)  
one   
If you answered one, the next questions are to diagnose this 
headache. Please start at question 18. 
17 
more than 
one  
 
 
If you answered more than one, please start also at question 
18 but from now on focus only upon the headache type that 
on the whole bothers you most (ie, interferes most with 
your life). 
 
Diagnostic questions 
 
How often do you have this type of headache? 
(please tick box or enter the number of days per month or per year) 
 
18 
everyday  ________days/month ________days/year 
How long does this type of headache usually last? 
(please enter the number of minutes, hours or days) 
 
19 
_____ min     _____hr     or     _____ days 
 
Is your last answer (to question 19) with or without having taken medication? 
(please tick one box) 
with    
20 
without  (if you answered “without medication”, please go to question 22) 
How long would it last if you did not take medication? 
(please enter the number of minutes, hours or days) 
 21 
_____ min      _____hr  or  _____ days 
 
How bad is this headache usually?  (please tick one box) 
 22 
not bad  bad  very bad  
There are many ways of describing a headache, but most headaches are either throbbing or 
pressing. 
Thinking still of this type of headache, which best describes the pain? (please tick one box) 
 
throbbing or pulsating 
(this means varying in time with the 
heart beat) 
 
23 
pressing, squeezing or tightening 
 
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Is the pain of this headache usually on only one side of the head? (please tick one box) 
 24 
no  yes  
Does exercise (like walking or climbing stairs) tend to make it worse? (please tick one 
box) 
 25 
no  
yes  
 
Thinking still of this type of headache, how does it affect your ability to do day-to-day 
activities? (please tick one box) 
 
can do everything as normal  
cannot do some things  
26 
can do nothing 
 
 
 
With this headache, do you usually feel sick (as though you may throw up)? 
(please tick one box) 27 
no  
yes  
 
With this headache, are you usually actually sick (do you throw up)? (please tick one box) 
 28 
no  
yes  
 
When you have this type of headache, does daylight or other lighting bother you? In other 
words, do you prefer to be in the dark? (please tick one box) 
(this question refers to ordinary levels of light, not bright lighting) 
 
29 
no  
yes  
 
When you have this type of headache, does noise bother you? In other words, do you 
prefer to be in the quiet? (please tick one box) 
(this question refers to ordinary levels of noise, not very loud noise) 
 
30 
no  
yes  
 
Has a doctor ever given you a diagnosis for this headache? 
(please tick one box and, if applicable, enter the diagnosis) 
 
no   31 
yes  
If yes, please write the diagnosis: _________________________ 
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The next series of questions are specifically about any headache you had yesterday (the day 
before you fill in your answers). This may be the same headache as the one you have just been 
describing, or it may be a different type of headache if you have more than one type. 
It is very important that the answers you give are about yesterday and not any other day. 
 
 
 
Questions about yesterday 
 
 
Did you have a headache yesterday? (please tick one box) 
 
no  (if no, go directly to question 44) 
32 
yes   
 
Was this the type of headache you have just been describing? (please tick one box) 
no   33 
yes 
 
 
 
 
 
Please now think about the headache you had yesterday. How long did it last? 
(please tick one box) 
less than 1 hour  
1-4 hours  
5-12 hours  
34 
more than 12 hours  
 
How bad was your headache yesterday?  (please tick one box) 
 
35 
%ot bad  Bad  Very bad  
 
Please now think about everything you wanted to do yesterday if you had not had a 
headache. 
How much of this did you actually do?  (please tick one box) 
 
%othing  
less than half  
more than half  
36 
everything  
 
Was yesterday a workday for you (either at your job or at school)?  (please tick one box) 
no  (if no, go directly to question 41) 
37 
yes   
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Because of your headache, were you absent from work or school yesterday? 
(please tick one box) 
 
%o  
Absent less than half the day  
Absent more than half the day  
38 
Absent the whole day  
(if absent the whole day please go to question 
40) 
 
 
If you went to work or school with your headache yesterday, how much of your work did 
you get done?  (please tick one box) 
 
%othing  
less than half  
more than half  
39 
everything  
(if everything, please go to question 41) 
 
 
Will you be able to make up for this today or later?  (please tick one box) 
 
40 
no  yes  
 
This question is about household work or general chores that you wanted to do yesterday 
if you had not had headache. 
How much of this did you actually do? (please tick one box) 
 
%othing  
less than half  
more than half  
41 
everything  
 
 
 
This question is about leisure and social activities that you wanted to do yesterday if you 
had not had headache. 
How much of this did you actually do?  (please tick one box) 
 
nothing  
less than half  
more than half  
42 
everything 
 
 
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What treatment did you take for the headache you had yesterday? 
(please tick the box if you took nothing; otherwise, please list the names and amounts of 
all medications taken yesterday) 
nothing at all  
 
 
List medications: 
(please list medications for headache, not for any other 
illnesses) 
how many times you took each 
yesterday 
43 
__________________________________  
 
 
 
Health care questions 
The aim of the following questions is to help us know how much health care should be available 
to meet the needs of people with headache. 
 
Many different medications may be used to treat headache. This question is about any of 
these medications you may have taken for headache in the last 30 days 
Please tick the first box if you took nothing at all in the last 30 days. Otherwise, please 
look at these lists, and think about which of these you have used in the last 30 days. 
Please tick one box by each medication. 
 
%othing at all    
 
%ot 
used 
Used 
once 
Used 
more 
than 
once 
almotriptan (Almigran)    
eletriptan (Relert)    
naratriptan (%aramig)    
rizatriptan (Maxalt)    
Sumatriptan, Imitrex, Merck-sumatriptan 
(Finigraine) 
   
zolmitriptan (Zomig)    
ergotamine Dihydergot, Dystonal (Cafergot)    
domperidone Motilium (Zilium)    
Metoclopramide Primperan, (Docmetoclo, Dibertil)    
Aspirine Acetylsalicylique acide (Sedergine, Dispril)    
Diclofenac Voltaren, Motifene    
Ibuprofene Brufen, %urofen, Spidifen,(Advil-mono)    
%aproxene Aleve, Apranax (%aprosyne)    
Paracetamol Dafalgan, Panadol, perdolan (dolprone)    
Proprietary combination drugs:    
44 
Migpriv (acetylsalicylate lysine, metoclopramide  
 
   
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Please list any other medications you have used to treat your headache in the last month? 
 
%ame(s) of medication(s): 
(please list medications for headache, not for any 
other illnesses) 
Used once 
Used more than 
once 
_______________________________________   
_______________________________________   
_______________________________________   
_______________________________________   
44 
cont 
 
Medications to prevent headaches are usually taken daily. Are you taking any of these? 
Please enter the name(s) and, by each one, for how long in weeks or months you have been 
taking it. 
 
%ame(s) of medication(s): Weeks Months 
_______________________________________ ________ ________ 
_______________________________________ ________ ________ 
   
   
45 
   
Botulinum toxin (Botox or Dysport) is used sometimes as a treatment for headaches, 
although it is not proven to be helpful. 
Have you been treated with Botulinum toxin for your headaches in the last year? 46 
no  
 
yes  
 
Many people with headache treat themselves, but others need professional advice. 
Have you had professional advice about your headaches in the last year? Who from, and 
how many times? 
Please tick all boxes that apply and, for each ticked box, enter the number of times in the last 
year. 
 
no-one   
  %umber of times 
nurse  ________ 
physical therapist 
(physiotherapist, osteopath, chiropractor) 
 ________ 
primary-care doctor (GP)  ________ 
headache specialist  ________ 
hospital emergency room  ________ 
other (please specify):__________________ 
 
 ________ 
47 
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Most people with headache do not require any investigations, but occasionally these tests are 
done. 
Because of your headaches, have you had any of these tests in the last year? 
(please tick all that apply) 
 
MRI brain scan  
CT brain scan  
x-rays of the neck  
eye tests (for glasses)  
blood tests  
other (please specify): ____________________  
48 
%one of the above 
 
 
 
Have you, in the last year, been admitted to hospital because of your headaches? 
(please tick the no or yes box and, if yes, also tick the box to indicate the total number of 
days you spent in hospital) 
 
%o   
yes  
 
 
If yes, how many days: 
1  
2  
3-7  
49 
More than 7 
 
 
 
 
Impact questions 
The next questions are about the effects your headaches have on your own life 
 
 
Have your headaches interfered with your education? 
(please tick all boxes that apply because of your headaches) 
 
no  
yes, I did less well  
50 
yes, I gave up early  
  
100 
Do you believe your headaches have made you less successful in your career? 
(please tick all boxes that apply because of your headaches) 
(if this question is not applicable to you, please tick no and go directly to question 54) 
no  
yes I have done less well  
Yes I have taken an easier job  
Yes I have taken long-term sick leave  
Yes, I have retired early  
51 
Yes, I am on a disability pension  
Have your headaches resulted in reduced earnings? (please tick one box) 
(if this question is not applicable to you, please tick no and go directly to question 54) 52 
no  yes  not applicable  
Do you feel that your employer and work colleagues understand and accept your headaches? 
(please tick one box) 
 
53 
no  yes  not applicable  
Do you feel that your family and friends understand and accept your headaches? 
(please tick one box) 54 
no  yes   
Do you avoid telling people that you have headaches?   (please tick one box) 
 55 
no  yes   
Taking into account everything you do to treat your headaches, do you feel you are in 
control of your headaches?   (please tick one box) 
 56 
always  often  sometimes  rarely  never  
 
 
The next questions are about lost time because of your headaches. 
 
57 
On how many days in the last 3 months could you not go to work or school because of 
your headaches? (please enter the number of days missed completely during the last 3 months) 
  __________ 
 
58 
On how many days in the last 3 months could you do less than half your usual amount in 
your job or schoolwork because of your headaches? 
(please enter the number of days; do not include days you counted in question 57 where you 
missed work or school)   __________ 
 
59 
On how many days in the last 3 months could you not do any household work because of 
your headaches?(please enter the number of days lost completely during the last 3 months) 
 __________ 
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60 
On how many days in the last 3 months could you do less than half your usual amount of 
household work because of your headaches? (please enter the number of days; do not include days 
you counted in question 59 where you did not do any household work) 
   __________ 
61 
On how many days in the last 3 months did you miss family, social or leisure activities 
because of your headaches?  (please enter the number of days) 
   __________ 
The following questions aim to understand how much your headaches affect you even when you 
do not actually have an attack. 
Please think carefully about the last day when you did not have a headache. 
 
On that day, were you anxious or worried about your next headache episode? 
(please tick one box) 
 
62 
no  yes   
On that day, was there anything you could not do or did not do because you wanted to 
avoid getting a headache?    (please tick one box) 
 
63 
no  yes   
On that day, did you feel completely free from all headache-related symptoms? 
(please tick one box) 
 
64 
no  yes   
The next three questions are about the effects your headaches have on your relationships, love 
life and family planning. 
Please answer no to any that do not apply. 
 
Have your headaches affected your family planning? 
(please tick all boxes that apply because of your headaches) 
no  
Yes, I have had fewer children  
Yes, I have avoided having children  
(the next answer is only for women)  
65 
Yes, I have avoided oral 
contraception 
 
During the last 3 months, have your headaches caused difficulties in your love life? 
(please tick one box) 66 
no  yes   
Have your headaches caused a relationship to break down?   (please tick one box) 
no  
Yes, they have caused separation  67 
Yes, they have caused divorce 
 
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Do you have children of school age (please tick one box) 
no     If you ticked no, please go directly to question 71 
68 
yes  
 
During the last 3 months, have your headaches caused one or more of your children to miss 
school? (please tick one box) 
no    
69 
yes   if yes, estimate the total number of missed days: ______ 
 
During the last 3 months, have your headaches prevented you from caring for your 
children?  (please tick one box)  
70 
no  once  
more than once  
 
 
Are you currently living with a partner (please tick one box)  
 
no      
71 
yes  if you are not now living with a partner, please go directly to question 79 
 
During the last 3 months, have your headaches caused your partner to lose time from 
work?  (please tick one box)  
 
no    
72 
yes   
if yes, enter the total number of days lost:   ______ 
 
 
During the last 3 months, have your headaches caused your partner to miss social 
activities?  (please tick one box) 
 
no    
73 
yes   
if yes, enter the total number of occasions missed:   ______ 
 
 
 
The next five questions are about your household partner. Whether you have headaches yourself 
or not, we would like to know if your partner has headaches and, if so, how they affect your life 
 
Has your partner had a headache in the last year?  (please tick one box) 
 
no   if no, go directly to question 79 74 
yes   
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75 
 
During the last 30 days, on how many days did he/she have a headache? 
(please enter the number of days between 0 and 30) 
_________days 
 
During the last 3 months, have your partner’s headaches caused you to lose time from 
work? 
 
76 
no  once  more than once  
 
During the last 3 months, have your partner’s headaches caused you to miss social 
activities?  (please tick one box) 
 
77 
no  once  more than once  
 
During the last 3 months, have your partner’s headaches caused difficulties in your love life? 
(please tick one box) 
 
78 
no  yes   
 
The next three series of questions are general, to be answered by everyone, with or without 
headaches. 
 
 
Body mass index questions 
Your answers to these questions will give an indication of your level of fitness. 
 
 
What is your weight? 
(please enter your weight in kilograms or in stones and pounds) 
________ kg 
79 
 
 
What is your height? 
(please enter your height in centimeters or in feet and inches) 
________ cm 
80 
 
 
What is your waist measurement? 
(please enter the measurement in centimeters or in inches) 
Please take a tape measure and put it around your waist or take a string put it around your 
waist and then measure the length of the string with a ruler  
________ cm 
81 
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Quality of life questions (WHOQoL) 
This set of eight questions, developed by the World Health Organization, are for everybody, 
whether they have headaches or not. They will help us compare people with headaches and 
people without. 
The questions ask how you feel about your quality of life, health or other areas of your life. Each 
question has five response options. Please choose the answer that appears most appropriate 
by ticking the box in the appropriate column. If you are unsure about which response to give 
to a question, the first response you think of is often the best one. 
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you think about 
your life in the last 4 weeks. 
 
  
very poor poor 
neither 
poor nor 
good 
good very good 
82 How would you rate your 
quality of life? 
 
     
  
very 
dissatisfied 
dissatisfied 
neither 
satisfied 
nor 
dissatisfied 
satisfied 
very 
satisfied 
83 
How satisfied are you with 
your health? 
 
     
84 
How satisfied are you with 
your ability to perform your 
daily living activities? 
 
     
85 
How satisfied are you with 
yourself? 
 
     
86 
How satisfied are you with 
your personal relationships? 
 
     
87 
How satisfied are you with 
the conditions of your living 
place? 
 
     
88 Do you have enough energy 
for everyday life? 
 
     
89 Have you enough money to 
meet your needs? 
     
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Depression and anxiety questions (HADS)  
The final series of questions ask about depression and anxiety, both of which are common in the 
general population. Please read each item and place a firm tick in the box which comes closest to 
how you have been feeling in the past week. Don't take too long over your replies: your 
immediate reaction to each item will probably be more accurate than a long thought out response. 
 
  
Most of the 
time 
A lot of the 
time 
Time to 
time, 
occasionally 
%ot at all 
90 
I feel tense or 
“wound up” 
3 2 1 0 
  %early all of 
the time 
Very often Sometimes %ot at all 
91 
I feel as if I am 
slowed down 
3 2 1 0 
  
Definitely as 
much 
%ot quite so 
much 
Only a little %ot at all 
92 
I still enjoy the things 
I used to enjoy 
0 1 2 3 
  %ot at all Occasionally Quite often Very often 
93 
I get a sort of 
frightened feeling 
like “butterflies in 
the stomach” 
0 1 2 3 
  Very 
definitely 
and quite 
badly 
Yes, but not 
too badly 
A little, but  
it doesn’t 
worry me 
%ot at all 
94 
I get a sort of 
frightened feeling 
like something 
awful is about to 
happen 
3 2 1 0 
  Definitely 
I don’t take 
as much 
care as I 
should 
I may not 
take quite as 
much care 
I take just as 
much care 
as ever 
95 
I have lost interest 
in my appearance 
3 2 1 0 
  As much as 
I always 
could 
%ot quite so 
much now 
Definitely 
not so much 
now 
%ot al all 
96 
I can laugh and see 
the funny side of 
things 
 
0 1 2 3 
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  Very much 
indeed 
Quite a lot 
%ot very 
much 
%ot at all 
97 
I feel restless as if 
I have to be on the 
move 
3 2 1 0 
  
A great deal 
of the time 
A lot of the 
time 
From time 
to time but 
not too often 
Only 
occasionally 
98 
Worrying thoughts 
go through my 
mind 
3 2 1 0 
  
A much as I 
ever did 
Rather less 
than I used 
to 
Definitely 
less than I 
used to 
Hardly at all 
99 
I look forward 
with enjoyment to 
things 
0 1 2 3 
  
%ot at all %ot often Sometimes 
Most of the 
time 
100 I feel cheerful 3 2 1 0 
  Very often 
indeed 
Quite often 
%ot very 
often 
%ot at all 
101 
I get sudden 
feelings of panic 
3 2 1 0 
  Definitely Usually %ot often %ot at all 
102 
I can sit at ease 
and feel relaxed 
0 1 2 3 
  Often Sometimes %ot often Very seldom 
103 
I can enjoy a good 
book or radio or 
TV programme 
0 1 2 3 
 
 
 
6    Discussion  
 
My dissertation shows that despite the advances in understanding the pathogenesis of migraine 
and other primary headache disorders, the existence of well-established diagnostic criteria and the 
availability of effective and safe treatments for headache disease-management, migraineurs and 
other primary headache sufferers continue to experience significant pain and disability (1).  
The physical, emotional, social and economic burdens of headache are poorly acknowledged 
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compared to less prevalent neurological disorders (2).  
So far there was no reliable comparable data on the different dimensions of headache 
burden in Europe. There was also no valid instrument for measuring the different dimensions of 
headache burden and no definition of indicators to build such an instrument. The impact of 
migraine for example has been mostly estimated based on pharmaceutical company studies on 
migraine and the loss of productivity at work, these studies being realized with the main objective 
to obtain an optimal price for the migraine attack treatment drug of the company (3).  
With my studies we could demonstrate for the first time that it was possible to realize 
pharmaceutical industry independent studies in that area of research. We could also proof that in 
headache disorder it was possible for different stakeholders (medical professions and patient 
organisations) to work together in a consortium, to develop together the first instrument 
(BURMIG) to evaluate the different dimensions of migraine burden in a multicultural 
environment and to develop together the first instrument (EUROLIGHT) to evaluate the different 
dimensions of headache burden at European level.  
Choosing Luxembourg as the country to do the multicultural test run for the validation of 
the BURMIG instrument proved to be a good choice. Until then Luxembourg was not known as 
European scientific point of interest in the neurological field. 
I haven chosen Luxembourg not only because it is my home country but with its multicultural 
aspects and languages, is well suited for a pilot European project. The country offers a clear 
structure and for this similar reason surveys about headaches have been made and publicized 
years ago in the republic of San Marino (4). 
There was no existing data about prevalence and impact of headache in Luxembourg and 
based on the BURMIG questionnaire we developed and validated in my second study, we could 
recently present the first prevalence and impact results for migraine in Luxembourg (5,6). 
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After the successful validation of the EUROLIGHT instrument we could start in October 
2008 to use the EUROLIGHT instrument for collecting the data of the different dimensions of 
headache burden in 10 European countries (France, Germany, Ireland, Spain, Netherlands, Italy, 
Austria, UK, Luxembourg and Lithuania) representative of the different regions of Europe, 
involving in each country a non-headache sufferers group as a control group.  
The European scientific research body on headache disorders, the European Headache 
Federation (EHF), has officially signed an agreement as associative partner for our Eurolight 
research and has committed themselves to base the next European Headache Treatment 
Guidelines presented at the European Headache Congress in Nice (France) in September 2010 on 
the outcome of the data from the EUROLIGHT questionnaire.  
Our 3 studies got also accepted by the World Health Organisation as an official activity 
contribution to the World Health Organisation campaign ‘Lifting the burden’  
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7   Conclusion 
Without knowing the size and dimensions of the burden of a health problem it is difficult to make 
clear recommendations about disease-management, the content of medical profession education 
and to raise public awareness. The future will show whether my work of developing the first 
instruments to measure in a reliable way the different dimensions of headache burden as well as 
measuring the problems in headache disease-management will, together with  the resulting new 
treatment guidelines, prompt health care providers and decision makers to re-examine clinical 
and pharmacy practice patterns and lead to better care.  
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